Patent Grant
11596517
The disclosed invention relates to the field of surgical grafts for the repair of bone defects, more particularly, surgical grafts that include demineralized bone particles.
Cohesive masses of demineralized cortical bone fibers have been used as bone void fillers or implants for use in general orthopaedic applications, trauma applications, and spinal applications, as well as for repair of craniomaxial defects, dental defects, and other bony defects. Such bone void fillers and implants absorb liquids, such as saline, blood, or bone marrow aspirate, but are slow to wet upon initial contact with a liquid. Further, the hydrated mass of fibers in such implants tends to lack structural strength such that it breaks apart when manipulated or irrigated.
Demineralized cortical bone fibers may be modified to improve certain properties of cohesive masses of such fibers that affect their usefulness as surgical grafts for bone repair. Such properties include wettability (i.e., surface tension or hydrophilicity), structural stability after compression, reduced swelling upon hydration, resistance to wash-out of fibers during irrigation, and ease of molding the fiber masses in their hydrated form. In a process according to an embodiment of the present invention, the wettability of the demineralized cortical bone fibers is increased by treating them with a biocompatible polar molecule. In an embodiment, the polar molecule comprises one or more of an alcohol, a polyol (e.g., a glycol or a glycerol), a sugar, a ketone, an aldehyde, an organic acid, or another biocompatible polar organic compound. In a process according to an embodiment of the present invention, the wettability of the demineralized cortical bone fibers is increased by treating them with a salt solution, such as saline solution or phosphate buffer. In a process according to an embodiment of the present invention, the wettability of the demineralized cortical bone fibers and/or masses of cortical bone fibers are modified by exposing them to an energetic source such as ultraviolet (UV) radiation. Embodiments of the present invention also include demineralized cortical bone fibers prepared by the aforementioned processes, masses of such demineralized cortical bone fibers, and surgical grafts and implants that include such demineralized cortical bone fibers.
Other embodiments of the present invention include chemical cross-linking of the demineralized cortical bone fibers. Still other embodiments include modifying the surface tension of the fibers by increasing their surface roughness or by drying at least one surface of the implant in contact with an appropriate solid or mesh material.
In embodiments of the present invention, any of the aforesaid methods may be used to treat other forms of demineralized bone matrix, such as demineralized cancellous bone pieces, demineralized cortical bone pieces, or fragments of demineralized bone. The aforesaid methods may also be used to increase the wettability of fibers or other graft materials that include tissue types derived from suitable organs or other tissue sources, or the wettability and/or mechanical properties of masses of such tissue particles.
Embodiments of the present invention include UV containment chambers which enable optimal exposure of the implant to UV radiation, while protecting an operator from exposure to potentially harmful UV radiation. Such containment chambers are specially designed for specific embodiments of the energetic cross-linking process.
For a more complete understanding of the present invention, reference is made to the following detailed description of exemplary embodiments considered in conjunction with the accompanying figures, in which:
Embodiments of the present invention include methods of treating demineralized bone particles to increase the wettability (i.e., surface tension or hydrophilicity) of the particles and modify the wettability and structural properties of implants including such particles. Although the exemplary embodiments presented herein describe the treatment of demineralized cortical bone fibers, the methods may be extended to the treatment of other demineralized bone matrix particles, such as demineralized cortical bone pieces, demineralized cancellous bone pieces, or corticocancellous bone pieces. The methods discussed herein may also be used to treat particles and implants derived from other tissue types. It is noted that the demineralized bone matrix particles and/or other tissue types may be used to make autografts, allografts or xenografts. All such options are within the contemplation of the methods and articles described hereinafter.
“Demineralized bone matrix” (DBM) refers to a bone-derived material that has osteoconductive and osteoinductive activity. DBM may be prepared by acid extraction of allograft bone, resulting in loss of most of the mineralized component but retention of collagen and noncollagenous proteins, including growth factors. Calcium can also be extracted from bone using such compounds as guanidine, ethylenediaminetetraacetatic acid (EDTA), urea, or other compounds that can form soluble complexes with calcium. DBM can be prepared in batch processes (e.g., in a flask, beaker, or other container), by a static or agitated soak, or in a flow-through apparatus whereby the bone is maintained in the apparatus while the demineralizing solution flows through. In agitated soaks, the bone is agitated in the demineralizing solution using methods that employ shaking, stirring, vibration, or ultrasonic techniques. Methods for preparing demineralized bone matrix from bone are known in the art, as disclosed, for example, in U.S. Pat. Nos. 5,073,373; 5,484,601; and 5,284,655, which are incorporated by reference herein. DBM may be prepared from autologous bone, allogeneic (or “allograft”) bone, or xenogeneic bone. DBM may be prepared from cancellous bone, cortical bone, corticocancellous bone, or combinations of cancellous, cortical and corticocancellous bone.
“Demineralized cortical bone fibers” (“DCBF”) refers to elongated particles of DBM derived from cortical bone, which have a length that is at least twice as great as the thickness and width of the fiber. Elongated particles of other tissue types discussed in this disclosure are also “fibers” for the purpose of this disclosure when they have respective lengths that are at least twice as great as their respective thicknesses and widths.
DCBF, according to embodiments of the present invention, may be derived from the cortical component of the long bones of the femur, tibia, humerus, radius, ulna, and fibula, or other suitable long bones of a mammal. Suitable mammal sources for DCBF include, without limitation, human, bovine, ovine, caprine, and porcine sources. The cortical bone is first stripped of all soft tissue elements and then cleaned using detergents/surfactants to remove residual blood and lipids from the bone surface. The cleaned cortical bone is then processed into elongated particles using a milling process that results in fibers that range in size from about 10 μm to about 1000 μm in thickness, about 20 μm to about 20 cm in length and about 5 μm to about 1 cm in width. The cortical fibers are demineralized in dilute acid resulting in a residual calcium content ranging from less than 15% w/w for partially demineralized fibers, less than 8% w/w for demineralized fibers, and less than 1% w/w for substantially or fully demineralized fibers. The calcium content of the fully demineralized fibers may be negligibly small, such that the fibers consist essentially of collagen, non-collagen protein, including glycoproteins, growth factors, and other non-mineral substances found in the original bone, although not necessarily in their original quantities. In other embodiments of the present invention, blocks of cortical bone are demineralized, and the fibers are subsequently produced by crushing or shredding the demineralized blocks.
The demineralization process is carefully controlled via the concentration of acid and duration of soak time in order to enhance the mechanical properties of the fibers while retaining the osteoinductive components that are exposed by the dilute acid reagents. Following demineralization, the tissue goes through a pH restoration process where the residual acid is neutralized by buffering reagents thereby returning the tissue to near physiological pH of between 6-8 pH. Subsequently, the demineralized cortical bone fibers may be stored in a wet state or dried using lyophilization or other drying techniques. The DCBF may be stored at various temperatures including but not limited to ambient room temperature (e.g., at about 23° C.), refrigerated (e.g., at about 4° C.), frozen (e.g., at about −20° C.), or cryogenically preserved (e.g., at about −196° C.) using controlled rate or uncontrolled rate freezing.
The DCBF may be placed into an implant forming container, such as a jar or a mold, and formed into a variety of shapes including, but not limited to, thin sheets, cubes, discs and strips. More intricate geometries may also be formed including, but not limited to, curves, cutouts, compartments and patterning which can be determined by the shape of the implant forming container. DCBF stored in a wet state may be placed, for example, into molds directly, whereas dried DCBF will need to be rehydrated prior to being placed in molds. For example, when dried DCBF are used they are first disbursed into a liquid carrier to form a solution and then agitated to ensure even distribution of the DCBF in the solution in the mold. As also discussed hereinbelow, the liquid carrier used to form the solution may be, for example without limitation, water, aqueous saline solution, Sorensen's buffer, or phosphate buffered saline solution. In some embodiments, excess liquid from the wet or rehydrated tissue may be separated from the DCBF, drained and removed from the mold. In some embodiments, additional liquids (e.g. water, buffer, or saline) may be added to the tissue before and during the molding process. The liquids added to tissue before and during the molding process could optionally contain therapeutic factors, cytokines, growth factors, pharmaceuticals, antibiotics, free-radical scavengers, sugars, vitamins including, but not limited to, riboflavin and ascorbic acid, surfactants, DMEM medium, human or animal serum, or other additives. The addition or removal of liquid from the tissue also allows the density of the final implant to be controlled and production of an implant of uniform density. The mold may be composed of a single or multiple types of materials, including but not limited to metals, glass, plastics, silicone, Teflon®, and ceramics. In an embodiment, the vessel or package in which the demineralized cortical bone fibers are stored serves as the mold.
In an embodiment, the mold is micro-porous or meshed with pore sizes ranging up to 5 mm. In an embodiment, the mold includes a non-uniform material. In an embodiment, the mold has varying pore sizes or mesh sizes, with the pores or meshes having different sizes at different locations in the mold. In an embodiment, the mold may include a layer of material placed on the top of the DCBF, the layer being of the same material used elsewhere in the mold or of a different material. In embodiments, the layer is solid, porous, or meshed, or has another geometry appropriate to the intended use of the mold and implant to be produced therefrom.
In an embodiment, DCBF are in the form of a mass of DCBF, which are then used to prepare implants that may be used as bone void filler or bone graft extender in bony voids and gaps which have been surgically created or caused by traumatic injury to the bone. Implants and grafts, as used herein, refer to tissues, organs or components thereof that are transplanted from a donor to a recipient and include those transplanted between individuals of the same species (“allograft”), those donated and transplanted into the same individual (“autograft”), and those transplanted between individuals of different species (“xenograft”). Such implants may be used as a standalone treatment device or be applied in combination with one or more of a variety of bioactive osteogenic materials or cells that facilitate the reconstruction and healing of bone. Such implants may include particles of cortical, cancellous, or corticocancellous bone. Such particles may be partially demineralized, demineralized, fully demineralized, or may have most or all of their original mineral or calcium content.
In an embodiment, the DCBF are pre-hydrated in an aqueous buffer, or combined with a carrier, such as, but not necessarily limited to, the following: an isotonic solution; a sodium chloride solution at a concentration of about 0.1% to about 1%, more particularly, about 0.9%; a lactated Ringer's solution, with or without DSLR; phosphate buffered saline (“PBS”); platelet rich plasma (PRP); glycerin; lecithin; alginate; hyaluronic acid (HA); a derivative of HA; or sodium hyaluronate; or other suitable carriers known in the art. The term “carrier” as used herein refers to a pharmaceutically acceptable inert agent or vehicle for delivering one or more active agents to a subject, and often is referred to as “excipient.” The carrier must be of sufficiently high purity and of sufficiently low toxicity to render it suitable for administration to the subject being treated. The carrier may also comprise “biological components” added to the carrier, such as, but not limited to, DNA, RNA, short hairpin RNA (shRNA), small interfering RNA (siRNA), micro RNA (mRNA), polysaccharides, peptides, matrix proteins, glycosaminoglycans (e.g, hyaluronic acid), viral vectors, and liposomes. The carrier further should maintain the stability and bioavailability of an active agent added to the carrier.
In an embodiment, a mass of DCBF fibers (e.g., an implant) are provided to a surgeon, who can then add one or more of a carrier, bone marrow, blood, non-demineralized bone chips, etc., and then mold or reshape the mass into a preferred configuration according to anatomical or surgical needs in the operating room. The final form should be cohesive, moldable, and provide some resistance to irrigation when in the defect site, and leave minimal residue on the gloves of those handling it. When the mass is thus prepared, the surgeon can place it in a bone defect site, a site with two adjacent bone defects, or any non-bony defect where it is desired to form new bone or repair bone.
In an embodiment of the present invention, DCBF are prepared as described in Section I, above, and subjected to treatment with one or more chemical solutions to improve the wettability of the individual fibers and of the fibrous mass. The increased wettability can be obtained by changing the surface charge of the DCBF or changing the surface morphology and/or micro-geometry of the DCBF. The fibers or fibrous mass may be treated with such chemical solutions immediately before the pH restoration step, after the pH restoration step, or before the fibers or fibrous mass are dried. In an embodiment, the fibers or fibrous mass may be dried, then rehydrated prior to treatment with the chemical solution. Furthermore, the DCBF may be treated with such chemical solutions after formation of the implant and before any final drying or lyophilizing step, where applicable. Simplified flow charts of representative chemical treatment processes are shown in
The chemical treatment is performed by contacting the DCBF with one or more chemical solutions selected to improve the wettability of dried or lyophilized DCBF. In an embodiment, the DCBF are soaked in the chemical solution for a period of time from about 6 hours to about 48 hours, for example from about 12 hours to about 36 hours, for example from about 20 hours to about 28 hours. In an embodiment, the soak is a static soak. In an embodiment, the DCBF are agitated during the soak.
In an embodiment, the chemical solution is isotonic with blood. In an embodiment, the chemical solution includes a dissolved salt. In an embodiment, the chemical solution is a physiologically-balanced solution that includes a salt. In an embodiment, the chemical solution is a saline solution. In an embodiment, the solute in the chemical solution consists of sodium chloride (e.g., a 1M NaCl solution). In an embodiment, the chemical solution is Ringer's solution. In an embodiment, the chemical solution is a buffer solution containing a buffering salt. In an embodiment, the chemical solution includes a phosphate salt. In an embodiment, the buffer solution is a standard buffering solution containing a buffering salt. In an embodiment, the buffer solution is a standard phosphate buffered solution (e.g., PBS). In an embodiment, the chemical solution is Sorenson's Buffer. In an embodiment, the chemical solution is Hanks Buffered Salt Solution. In an embodiment, the chemical solution is a HEPES-buffered solution.
In an embodiment, the chemical solution includes a biologically-compatible polar organic compound. In an embodiment, the chemical solution includes an alcohol. In an embodiment, the chemical solution includes ethanol. In an embodiment, the chemical solution includes a polyol. In an embodiment, the chemical solution includes a glycol. In an embodiment, the chemical solution includes glycerol. In an embodiment, the chemical solution includes polyethylene glycol. In an embodiment, the chemical solution includes a sugar. In an embodiment, the chemical solution includes dextrose. In an embodiment, the chemical solution includes mannitol-D. In an embodiment, the chemical solution includes sodium ascorbate. In an embodiment, the chemical solution includes one or more of a ketone, an aldehyde, an organic acid, or another biocompatible polar organic compound. In an embodiment, the chemical solution includes an additive to inhibit proteolytic activity of proteinases (e.g., matrix metalloproteinases, “MMP”). In an embodiment, the additive is chlorhexidine gluconate. In an embodiment, the additive is galardin. In an embodiment, the chemical solution includes a combination of one or more biologically-compatible polar organic compounds and one or more dissolved salts. In an embodiment, the chemical solution is a non-aqueous solution. In an embodiment, a polar organic liquid is used in place of the chemical solution.
In an embodiment, the chemical solution includes a biologically-compatible polar organic compound and/or a dissolved salt, and an additive. In an embodiment, the additive is a therapeutic agent for administration to a mammal. In an embodiment, the additive is a cytokine. In an embodiment, the additive is a pharmaceutical. In an embodiment, the additive is an antibiotic. In an embodiment, the additive is a nutrient. In an embodiment, the additive is a trace element. In an embodiment, the additive is a free-radical scavenger. In an embodiment, the additive is a growth factor. In an embodiment, the additive is a biologically-active compound.
In an embodiment, the ratio of DCBF to the chemical solution is in a range of about 1:10 g/ml to about 1:1 g/ml. In an embodiment, the ratio of the DCBF to the chemical solution are selected to provide a desired fiber density and fractional void volume in the dried implant. In such an embodiment, lower ratios of DCBF to chemical solution result in less dense implants with higher void volumes.
In some embodiments, the implants produced by the methods described and contemplated herein have uniform density. An implant may be tested for uniform density by various methods. One suitable method, for example without limitation, for determining whether an implant has uniform density is to measure the overall density of the implant, then divide or cut the implant into at least three portions and measure the density of each portion, to produce at least four measured density values for that single implant. The average density for that implant is calculated by dividing the sum of all densities (whole implant and all pieces) by the total number of pieces plus 1 (for the whole implant density). Next, the percent relative standard deviation (% RSD) for that implant is determined as a percentage by first determining the standard deviation of all the measured density values using conventional statistical analysis methods, and then dividing that standard deviation by the average density and multiplying by 100. As the term “uniform density” is used herein, an implant is considered to have uniform density when the % RSD is less than about 30%, such as less than about 25%, or less than about 20%, or less than about 15%, or less than 10%. Example 26 provides an example of such calculations.
Following treatment with the chemical solution, the treated DCBF are dried. In an embodiment, the treated DCBF are dried by air drying. In an embodiment, the treated DCBF are dried by vacuum filtration. In an embodiment, the treated DCBF are dried by heat-drying. In an embodiment, the treated DCBF are dried by solvent-drying. In an embodiment, the treated DCBF have a residual moisture content of less than 80% after drying. In an embodiment, the treated DCBF have a residual moisture content in a range of about 60% to about 80% after drying.
In an embodiment, the treated DCBF are dried by lyophilization. In an embodiment, the treated DCBF are frozen before being lyophilized. In an embodiment, the treated DCBF are refrigerated before being lyophilized. In an embodiment, the treated DCBF are staged at room temperature before being lyophilized. In an embodiment, the treated DCBF are dried to a residual moisture content of less than 80% before being lyophilized. In an embodiment, a quantity of a chemical solution is added to the dried DCBF, and the solvent is removed from the DCBF fibers by lyophilization. In an embodiment, the ratio of treated DCBF to chemical solution is in a range of about 1:0.8 (g/ml) to about 1:10 (g/ml) before lyophilization. In an embodiment, the treated DCBF have a residual moisture content of less than 6% after lyophilization.
In an embodiment, wet-treated DCBF (i.e., DCBF treated with a chemical solution) are placed in an implant forming container, such as a mold, prior to lyophilization, such that the lyophilized DCBF mass takes the shape of the mold. In an embodiment, wet treated DCBF are placed in a jar or other container, then lyophilized. The final tissue form, or implant comprising treated dried DCBF, may then be provided to medical personnel for use as discussed in Section I, above.
As shown
In an embodiment of the present invention, lyophilized DCBF treated using the methods described above are rehydrated prior to use. In an embodiment, lyophilized DCBR treated according to the methods described above are rehydrated prior to being packaged. In embodiments of such rehydration, the lyophilized DCBF are mixed with PBS, with or without other of the substances described above with respect to chemical solutions. In an embodiment, ratio of DCBF/PBS is selected to generate a cohesive, moldable composition that includes completely hydrated DCBF. In an embodiment, the mixture is in a range of about 20:80 DCBF/PBS (g/ml) to about 34/66 DCBF/PBS (g/ml).
In an embodiment of the present invention, the surface roughness of the DCBF is modified using a surface modification technique known in the art or to be discovered. Known suitable techniques include, without limitation, overcoating, surface gradient modification, surface-active bulk additives, surface chemical reactions, etching, roughening, conversion coatings, ion beam implantation, Langmuir-Blodgett deposition, laser roughening, parylene coatings, photografting, radiation grafting, radiofrequency glow discharge plasma deposition, radiofrequency glow discharge treatment, self-assembled monolayers, silanization, surface-modifying additives, and other means of modifying surfaces of fibers. In an embodiment, one or more of the aforesaid techniques creates surface features on the micron scale, sub-micron scale, nano-scale, or other scales.
In an embodiment of the present invention, the wettability of an implant comprising modified or non-modified DCBF can be measured using standard methods for assessing surface tension, including but not limited to static and dynamic contact angle measurement techniques. Suitable contact angle measurement techniques include, but are not limited to, optical tensiometry, force tensiometry, Wilhelmy plate methods, sessile drop methods, captive air bubble methods, capillary air methods, the du Nouy ring method, or other measurement techniques for determining contact angles of liquid substances. In certain embodiments, DCBF implants prepared according to methods of the present invention may have at least one surface where the contact angle is less than 90 degrees, or less than 60 degrees, or less than 45 degrees. Another suitable method for measuring the wettability of an implant is, for example without limitation, by observing the rate at which a DCBF implant absorbs an amount of liquid. In an embodiment, the amount of liquid is a measured volume deposited on a surface of the implant and the measured value is known as wettability time. Implants produced according to the methods described and contemplated herein have a wettability time of less than about 5 minutes, such as less than about 4 minutes, or less than about 3 minutes, or less than about 2 minutes, or less than about 1 minute. Still another suitable method for measuring the wettability of an implant is, for example without limitation, submerging the implant in an excess amount of liquid and measuring the time required for the implant to absorb enough of the liquid to completely submerge the implant and the measured value is known as complete rehydration time. Implants produced according to the methods described and contemplated herein have a complete rehydration time of less than about 30 minutes, such as less than about 20 minutes, or less than about 15 minutes, or less than about 10 minutes, or less than about 5 minutes.
In an embodiment, the present invention includes an implant that is comprised of DCBF that have been either fully or partially cross-linked using energetic sources. Suitable energetic sources include ultraviolet (UV) radiation, ozone, plasma, (e.g., RF plasma), coronal discharge, or other means that provide the energy needed to form cross-links between proteins. Suitable plasma media include, but are not limited to, air plasma, oxygen plasma, and ammonium plasma. In an embodiment, energetic cross-linking binds proteins such as albumin or other blood adsorption proteins to the DCBF, otherwise affects the adsorption of the proteins to the DCBF, before lyophilization to increase the wettability of the DCBF implant. The wettability of the energetically cross-linked DCBF implants is measured using the same techniques described in Section II with regard to the chemical and surface treatment of DCBF.
Cross-linking imparts a variety of unique properties to the DCBF implant that a non-cross-linked implant would otherwise not possess. Such properties include increased wettability, shape retention under compression, and resistance to fiber washout. A simplified flow chart of a representative energetic cross-linking treatment process is shown in
In an embodiment of the present invention, DCBF are cross-linked by exposing a mass of DCBF to UV radiation. In an embodiment, wet DCBF are placed into a mold and formed into one of a variety of possibly desirable shapes. Such shapes include, but are not limited to, thin sheets, cubes, discs and strips. More intricate geometries may also be formed including, but not limited to, curves, cutouts, compartments and patterned shapes. In an embodiment, the mass is shaped to approximate a surface of an intact or damaged bone, such as to line a hip socket or the interior of a bone void.
In embodiments of the present invention, suitable molds may be composed of single or multiple types of material or combinations of materials. Such materials include, but are not limited to metals, glasses, plastics and ceramics. Suitable materials may either block UV radiation completely, partially transmit, or fully transmit UV radiation, allowing all or selected portions of the implant to be exposed to UV radiation. While most materials exhibit poor transmission of UV radiation, certain materials such as fused quartz or silica glass and plastics including, but not limited to, optical grade polystyrene and specialized PMMA acrylic (Plexiglas G-UVT, Solarcryl SUVT, Acrylite OP-4) allow for near full transmission of certain wavelengths of UV radiation. After molding the sample into its final shape, the implant may be left in the mold or removed from the mold before undergoing UV cross-linking. The implant may be lyophilized within or without the mold before undergoing UV cross-linking, or lyophilized and rehydrated again prior to UV cross-linking. The implant may also be further masked using materials that completely block or are partially transmissible to UV radiation to further control cross-linking in certain regions of the implant.
In embodiments of the present invention, the mold is a composite of various materials selected to provide variations in the degree of cross-linking across the implant. In an exemplary embodiment, the implant is formed with a cavity to receive an osteoinductive substances or other therapeutic material. In such an embodiment, it may be desirable that the bottom of the implant, opposite the cavity, may be more densely cross-linked to provide increased structural stability to the implant. In other embodiments, variations in cross-linking density may be used to allow certain sections of the implant to be remodeled at different rates than other sections during the bone remodeling process.
In an embodiment of the present invention, UV surface cross-linking is performed by placing the implant in a UV containment chamber and exposing the implant to UV radiation. The UV radiation alters the collagen molecules within the implant, resulting in additional bonds being formed between adjacent collagen molecules. This process of photopolymerization of collagen is believed to occur due to the generation of free radicals via photooxidation of sensitive amino acid residues by UV radiation. The free radicals generated allow the formation of covalent cross-links between the collagen polypeptides, resulting in stronger and stiffer collagen fibers. Aromatic amino acid residues are the predominant sites of free radical formation. Other amino acid residues may be the site of free radical generation under more energetic conditions. Further, the rate at which cross-linkages are formed may be increased by adding biologically-compatible free radical initiators to the DCBF mass. Riboflavin is an example of such an initiator. Other initiators may include other compounds with aromatic structures, or may include sugars.
The amount of liquid in the implant affects the rate and degree of cross-linking. Without being bound by theory, it is believed that the presence of liquid provides a medium for transport of free radicals between collagen fibers. While it is possible to cross-link dried or lyophilized fibers, the embodiments of cross-linking methods according to the present invention are most effective when used with rehydrated fibers. However, excess water may be added to the DCBF implant before cross-linking to swell the implant, thus increasing its porosity, and the exposure time increased, if necessary to achieve the desired amount of cross-linkage.
The rate and depth at which cross-linkages are formed may be controlled by altering the power of the UV radiation source, changing the distance of the implant from the UV radiation source, shifting the wavelength of the UV radiation, varying the exposure time, and by fully or partially blocking UV radiation transmission to certain areas of the implant. Multiple UV radiation sources may be used with a combined power rating ranging from a few watts to a few kilowatts. In high power or energy dense cross-linking implementations of the present invention, the UV containment chamber and implant may be cooled to temperatures ranging from physiological (e.g., about 37° C.) to freezing (e.g., about −80° C.) during the cross-linking process using any of a variety of cooling techniques to prevent heat-related degradation of the implant. Suitable cooling techniques include but are not limited to refrigerant-based cooling, active air cooling, thermoelectric devices, evaporative cooling, and phase-change cooling (e.g., the use of dry ice). The implant may also be placed under UV radiation for multiple short exposures instead of a single long exposure to reduce the amount of heat generated in the tissue. In some embodiments that involve UV cross-linking, it may be beneficial to heat the implant to a temperature that is higher than physiological temperatures (e.g., the implant may be heated to a temperature in a range of from about 37° C. to about 70° C.). Heat may be applied to the implant by the UV bulbs or an additional heating element. The implant may be placed on a heating platform and/or heated by UV bulbs placed around the implant. The addition of heat greater than about 37° C. but less than about 70° C. for lengths of time of from about 10 minutes to about 24 hours increases the cohesiveness of the implant and helps prevent dispersion of the implant when rehydrated or submerged in a rehydrating liquid (e.g., water, saline, blood). In some embodiments, the use of heat to improve the cohesiveness of the implant may be used without the addition of UV exposure.
In embodiments of a method according to the present invention, the intensity or irradiance of the UV radiation at the surface of the implant may be varied by the power of the radiation source and/or the distance between the implant and the UV radiation source. Suitable energy densities for use in a method according to an embodiment of the present invention range from about 100 μW/cm2 to about 5,000 mW/cm2 at the surface of the implant. The wavelength of the UV radiation can be shifted between various regions of the UV spectrum including but not limited to longwave UVA (e.g., about 400 to about 315 nm), midrange UVB (e.g., about 315 to about 280 nm), and shortwave UVC (e.g., about 280 to about 100 nm). Shifting the wavelength changes the penetration properties of UV radiation into the implant, with longer wavelengths allowing increased UV penetration and greater depth of cross-linking. For example, in an embodiment of the present invention, exposure to UVA radiation is used to create cross-linking to a depth of about 1 mm, which creates a stiff shell at the surface of the implant. Shifting wavelengths also changes the character of the cross-links, which affects the degree to which properties such as mechanical strength, shape memory retention, and hydrophobicity are modified. Concurrent exposure to UV radiation at differing wavelengths may be used to vary the changes in properties across the implant. Wavelengths in the UVC spectrum also have the added benefit of being germicidal, and thus can be used to sterilize the surfaces of the implant while it undergoes cross-linking.
The length of time that the implant is exposed to the UV radiation source also affects the degree and effectiveness of cross-link formation. In cross-linking methods according to embodiments of the present invention, suitable exposure times are in a range of a few seconds to a few hours depending on the desired properties of the implant. In some embodiments, exposure times of up to 720 minutes may be used, although typical exposure times of about 10 minutes or less may be used (e.g., for commercial production of implants). In some embodiments, even shorter exposure times (e.g., exposure times of about 10 seconds to about 300 seconds) may be used where only a small degree of cross-linking is desired, or where the UV radiation is particularly intense. For many embodiments, the practical exposure times would be in a range of about 10 minutes to about 60 minutes.
After the cross-linking process is completed, the implant may be stored in a wet state or dried using lyophilization, air drying, or other drying methods. The implant may be stored at various temperatures including but not limited to ambient room temperature (e.g., at about 23° C., or up to about 30° C.), refrigerated (e.g., at about 4° C.), frozen (e.g., at about −20° C.), or at cryogenic temperatures (e.g., at about −196° C.) where frozen or cryogenic freezing is achieved using controlled rate and/or uncontrolled rate freezing. By changing the variables discussed above before and during the cross-linking process, a broad range of implants with varying properties may be produced.
In an embodiment of the present invention, the cross-linking process is performed in a containment chamber that allows optimal UV irradiation while shielding an operator from potentially harmful UV irradiation. During the cross-linking process, the implant may be placed on a flat surface, an uneven surface with ridges and peaks, or elevated on a platform or by other means that would allow UV radiation to reflect onto all sides of the implant, including its underside. The surface or platform that the implant rests on could also be made of multiple types of materials that block UV radiation completely, partially transmit UV radiation, or fully transmit UV radiation. The walls of the UV containment chamber may be lined or coated with a reflective material to allow the radiation to scatter within the UV containment chamber, allowing all surfaces of the implant to be exposed to UV radiation. UV radiation sources may also be mounted on multiple walls of the UV containment chamber to allow for better coverage of the implant during the cross-linking process. The orientation of the implant may also be changed during the UV cross-linking process either manually or automated by the UV containment chamber for a more uniform exposure of all surfaces.
Embodiments of the UV cross-linking method of the present invention include the aforesaid containment chambers, which may be specially designed to meet the needs of specific embodiments of the UV cross-linking method. Containment chambers according to embodiments of the present invention may also be designed for use with energetic sources other than UV radiation sources, such as ozone, plasma, (e.g., RF plasma), coronal discharge, or other means that provide the energy needed to form cross-links between proteins. In an embodiment, the containment chamber includes means for positioning and/or moving the implant. In an embodiment, the containment chamber includes one or more sources of UV radiation.
In an embodiment of the present invention, the distance of an implant from a UV radiation source may be changed during the irradiation process using manually or automatically operated device to provide optimal UV irradiation for different types of implants. In an embodiment, the device includes a manual or automated moving platform upon which the implants rest. Such platforms can move along x-, y-, and z-axes. In an embodiment, the device includes single or multiple UV radiation sources that can move along x-, y-, and z-axes. In an embodiment, the UV radiation source is one or more UV lamps in a movable lamp fixture. In an embodiment, the device includes a rotating drum. In an embodiment, the device includes a rotating platform. In an embodiment, the device includes an orbiting platform.
The effectiveness of the irradiation process may be affected by the temperature of the implant and/or UV radiation source. In an embodiment of the present invention, the containment chamber includes a temperature control system for regulating the temperature of the implant during irradiation by heating or cooling the implant. In an embodiment of the present invention, the containment chamber includes a temperature control system for heating or cooling the radiation source. In an embodiment, the interior of the UV containment chamber is ventilated and/or cooled using one or more input and output ports to control heating of the implant during the UV irradiation process. In an embodiment, such ventilation and/or cooling is controlled by a controller that is operated manually or automatically in response to temperature measurements made at the implant or elsewhere in the interior of the containment chamber.
In an embodiment of the present invention, the UV radiation source includes one or more of a fluorescent lamp, a gas discharge lamp, a high-intensity discharge lamp, an electroluminescent lamp, a light-emitting diode, a laser, an incandescent lamp, an electron-stimulated lamp, and other devices that emit UV radiation at intensities suitable for cross-linking DCBF.
In an embodiment, a UV radiation controller is integrated in the containment chamber. The UV radiation controller includes one or more of means for opening and/or closing a shutter, means for turning one or more UV radiation sources on and/or off, means for controlling the brightness of the UV radiation source, and other means for controlling the intensity and/or duration of the irradiation of the implant. In an embodiment, a controller is provided, the controller having circuitry for controlling one or more of the aforesaid means. In an embodiment, the controller includes a computer. In an embodiment, the computer is programmable by an operator.
In an embodiment, the containment chamber includes one or more sensors to sense the intensity of UV radiation emitted by the UV radiation sources and/or the intensity of UV radiation at the surface of the implant. In an embodiment, a controller is provided, the controller having circuitry for controlling the intensity of the UV radiation source. In an embodiment, the controller controls the intensity of the UV radiation source in response to output from the one or more sensors. In an embodiment, the controller includes a computer. In an embodiment, the computer is programmable by an operator such that the UV radiation source provides UV radiation of a specified intensity and/or range or wavelengths. In an embodiment, the computer is programmable by an operator such that the UV radiation source provides a total irradiation energy to the implant.
In an embodiment, the UV containment chamber is designed to be used in one or both of a sterile and a non-sterile environment. In an embodiment where the environment is non-sterile, the implant is contained in a sterile interior of a separate UV-transmissive chamber that is placed in the UV containment chamber such that radiation from the UV radiation source is transmitted through the UV-transmissive chamber to the implant. In an embodiment, the interior of a UV containment chamber is maintained as a sterile environment by sealing the UV radiation source and controller circuitry in a separate compartment. In such an embodiment, the sealed compartment is UV transmissive such that UV radiation from the UV radiation source is transmitted from the sealed compartment into the interior of the UV containment chamber.
UV cross-linking of DCBF provides an implant with properties that an otherwise non-cross-linked implant would not possess. The current lyophilized formulations of demineralized cortical fibers have a few shortcomings that can be address by UV cross-linking. One such shortcoming is the initial resistance to rehydration of a lyophilized DCBF implant. When the implant has been lyophilized, the residual moisture level is typically no more than 6% w/w and this lack of moisture causes the implant to exhibit hydrophobic characteristics. When a liquid such as water, saline, or blood is applied to the surface of the implant, the liquid sits on the surface and is not immediately absorbed. Once the initial amount of liquid becomes absorbed into the implant, the rehydrated surface exhibits hydrophilic characteristics and any additional liquid added is immediately absorbed into the implant. Another shortcoming is the lack of mechanical strength and structural rigidity of a lyophilized DCBF implant after rehydration. In the lyophilized state, the implant holds its shape and is rather stiff, however, after the implant has been rehydrated, the implant becomes soft, the DCBF start to swell, and the implant cannot be handled without permanently losing its shape. In certain situations, it is preferable for the implant to retain its shape while also being compliant and flexible even after being saturated with liquid.
UV cross-linking allows the hydrophilicity and mechanical properties of a DCBF implant to be modified quickly and efficiently compared to other methods known in the art. However, an embodiment of the present invention include physical cross-linking by techniques such as those including dehydrothermal treatment (DHT). An embodiment of the present invention includes chemical cross-linking of DCBF by one or more known methods, or by a chemical cross-linking method yet to be discovered.
Known chemical cross-linking techniques include, but are not limited to, the use of glutaraldehyde, carbodiimide (e.g., 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, also known as EDC), EDC with NHS (i.e., N-hydroxysuccinamide), genipin, catechin, succinic acid, and tannic acid. While some chemical cross-linkers have been used in the past on various types of materials, including allograft tissue, chemical cross-linking can be a complicated and lengthy process, and is potentially hazardous to the patient if the residual chemicals are not completely removed. Natural chemical cross-linkers, such as genipin and catechin, are less cytotoxic than synthetic cross-linkers, but may also have disadvantages in some applications. In the case of genepin, the tissue is stained a dark blue as a result of the cross-linking process, and the stain is difficult to remove. Chemical cross-linking is also difficult to control and is more easily applied to the entire bulk of the implant rather than to specific areas or surfaces. Too much cross-linking of the implant may also impart properties that are unfavorable. One of the advantages of implants made from DCBF is that they are moldable and cohesive after rehydration. This property is diminished as the DCBF become more cross-linked, resulting in an implant that cannot be molded into a different shape or put together once it has been taken apart. Despite the aforesaid difficulties posed by chemical cross-linking techniques, their use in forming cross-linked implants, as well as the implants themselves, are useful embodiments of the present invention.
In contrast to the chemical cross-linking methods discussed above, cross-linking by UV radiation is easily controlled and can be implemented to prepare DCBF implants that have the advantages of both non-cross-linked and cross-linked DCBF, while eliminating the disadvantages of excessive stiffness and resistance to recombination of pieces of the implant. By using UV radiation to cross-link certain surfaces of the implant while leaving other areas uncross-linked, an implant is prepared that retains its shape after rehydration due to the increased stiffness of the cross-linked regions, while also retaining the moldable and cohesive properties of the uncross-linked regions. UV cross-linking also reduces the initial hydrophobicity encountered by the lyophilized demineralized cortical fibers allowing the implant to be rehydrated nearly instantaneously. Furthermore, UV cross-linking imparts some shape memory retention to the rehydrated implant. When an external force is applied, the cross-linked implant is temporarily deformed and some liquid is displaced. However, as soon as the force is removed, the cross-linked implant will return to its original shape and resorb the previously displaced liquid. Only when a sufficient amount of force is applied does the implant permanently deform and become moldable. Additionally, the increased rigidity of the cross-linked surfaces of the implant prevents the implant from breaking apart when an excess of liquid is applied, when the implant is irrigated, or when the implant is completely submerged in a liquid.
Embodiments of the cross-linking methods of the present invention can be used to produce hydrophilic and mechanically stable DCBF implants from fully demineralized, demineralized, or partially demineralized DCBF, but is most effective for cross-linking DCBF with calcium contents of less than 1% w/w. The UV cross-linking method of the present invention may be used with DCBF having thicknesses in a range of about 80 μm to about 150 μm, or at other thicknesses where the DCBF form a cohesive mass in the absence of cross-linkages. Further, embodiments of the energetic method of the present invention can be used to prepare DCBF implants in the presence of additives. Additives such as particles of non-demineralized cortical, cancellous, or corticocancellous bone, demineralized cortical, cancellous, or corticocancellous bone may be used as long as the implant contains sufficient DCBF to form a cohesive mass. Additives such as therapeutic factors, cytokines, growth factors, pharmaceuticals, antibiotics, free-radical scavengers, sugars, or other chemical or bioactive compounds will retain their effectiveness after exposure, since the energetic exposure, and thus cross-linking, occurs at and/or near the surfaces of the implant, and does not significantly affect the interior of the implant.
Although the exemplary embodiments of the energetic cross-linking process described herein discuss the use of UV radiation, one having ordinary skill in the art and possession of the present disclosure will recognize that other sources of energy may be used to cross-link protein-rich fibers. Besides UV radiation, suitable energetic sources include, but are not limited to, ozone, plasma, (e.g., RF plasma), coronal discharge, or other means that provide the energy needed to form cross-links between proteins. Suitable plasma media include, but are not limited to, air plasma, oxygen plasma, and ammonium plasma.
Without being bound by theory, it is believed that the increased wettability and other effects observed in DCBF and masses of DCBF that have been treated as discussed herein result from interactions with the collagen and/or glycoproteins present in cortical demineralized bone matrix. Thus, one having ordinary skill in the art and possession of the present disclosure would reasonably expect that similar beneficial results may be obtained by applying such treatments to demineralized bone matrix from cancellous or corticocancellous bone. One having ordinary skill in the art and possession of the present disclosure would also reasonably expect that similar beneficial results may be obtained by applying such treatments to fibers or other particles of tissue types other than demineralized bone matrix. Such other tissue types may be derived from any suitable organ or other tissue source, whether autologous, allogeneic, or xenogeneic. Examples of suitable xenogeneic sources of tissues include, but are not necessarily limited to, warm-blooded vertebrates, including mammals, such mammalian sources including human, bovine, ovine, caprine, and porcine sources. Suitable tissue types may include, but are not necessarily limited to an adipose tissue, an amnion tissue, an artery tissue, a bone tissue, a cartilage tissue, a chorion tissue, a colon tissue, a dental tissue, a dermal tissue, a duodenal tissue, an endothelial tissue, an epithelial tissue, a fascial tissue, a gastrointestinal tissue, a growth plate tissue, an intervertebral disc tissue, an intestinal mucosal tissue, an intestinal serosal tissue, a ligament tissue, a liver tissue, a lung tissue, a mammary tissue, a meniscal tissue, a muscle tissue, a nerve tissue, an ovarian tissue, a parenchymal organ tissue, a pericardial tissue, a periosteal tissue, a peritoneal tissue, a placental tissue, a skin tissue, a spleen tissue, a stomach tissue, a synovial tissue, a tendon tissue, a testes tissue, an umbilical cord tissue, a urological tissue, a vascular tissue, a vein tissue, and a combination thereof. Other suitable tissue types may include, but are not necessarily limited to, submucosa, renal capsule membrane, dermal collagen, dura mater, serosa, or basement membrane layers, including liver basement membrane. Suitable submucosa materials for these purposes include, for instance, intestinal submucosa, including small intestinal submucosa, stomach submucosa, urinary bladder submucosa, and uterine submucosa. Source tissue (i.e., tissue incorporated into a final processed product, such as an implant) of the types disclosed above may be separated from other tissue types adjacent or connected to the source tissue, or the adjacent or connected tissue may remain with the source tissue and become incorporated in the implant. One or more source tissues may be included in the final processed product.
The following examples are set forth so as to provide those of ordinary skill in the art with an exemplary disclosure and description of how to make and use the described invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.) but some experimental errors and deviations should be accounted for.
Human long bone is recovered aseptically from a deceased donor and stored at 4° C. until ready for processing. The bone is debrided to remove soft tissue elements and the shaft of the bone is cut into cross-sections. The cortical bone is then cleaned using detergents/surfactants to remove residual blood and lipids from the bone surface.
To create DCBF, the bone sections are first shaved across the shaft of the bone using a controlled advancement rate of a lathe bit having a width approximately equal to the desired length of the bone fibers. The shaft segment is secured in a vice with a sufficient portion of the shaft protruding such that the protruding portion may be shaved. On a milling machine, a straight flute end-mill is set up such that its axis is parallel with the axis of the shaft. Utilizing the required length of the of the broad edge of the lathe bit, fibers are shaved off of the shaft by running the end-mill back and forth along the shaft until substantially all of the bone has been shaved from the shaft. The resulting bone fibers are collected for demineralization.
The bone fibers are demineralized by agitating them in 0.6 N HCl for a sufficient period of time to remove the endogenous calcium minerals to a desired residual calcium content, after which the fibers are successively rinsed with water, soaked in water, soaked in a sodium phosphate dibasic buffer to achieve a physiological pH, rinsed in water, and soaked in water. The soaked fibers may then be dried, lyophilized, or left in a wet state for further processing.
DCBF are prepared as described in Example 1. After completion of the second water soak, the DCBF are decanted into a vessel, and PBS is added at a ratio in a range of about 1:3 DCBF/PBS (g/ml) to about 1:15 DCBF/PBS (g/ml). After 5 to 15 minutes of a static soak, the DCBF are decanted from the PBS, and air-dried. Additional PBS is added to the DCBF at a ratio in a range of about 1:1 DCBF/PBS (g/ml) to about 1:5 DCBF/PBS (g/ml) in a plastic jar, and the wet DCBF are lyophilized.
Low-density pre-formed fiber shapes are lyophilized DCBF which are suspended in liquid prior to lyophilization to provide a fluffy texture and a high void volume. They are hydrated by a surgeon in the operating room to form a putty-like substance for use as a bone void filler.
Low-density pre-formed fiber shapes were prepared using water or different ratios of 0.9% sodium chloride in water (“saline”, in particular 0.25× saline, 0.5× saline, 0.75× saline, and 1× saline) to examine the effect of salt concentration on hydration time and handling properties of the implants. The samples prepared with water were used as control samples; the samples prepared with saline solutions were examined as test samples.
Samples of air-dried DCBF prepared according to Example 1 were soaked in water or saline at selected concentrations at a ratio in a range of about 1:3 DCBF/liquid (g/ml) to about 1:15 DCBF/liquid (g/ml) for 5 to 15 minutes, after which they were air-dried on a vacuum sieve. The samples were then lyophilized. Some samples were lyophilized in open jars; others were lyophilized with a vented lid, the ventilation holes having been covered by a porous liner having a pore size of greater than 10 μm. The lyophilized samples were then tested for hydration time and handling properties.
Test samples prepared with PBS and lyophilized with a lid and porous liner hydrated more rapidly than the control samples prepared with water. There was no significant difference in the handling of any of the test samples in comparison to the control samples.
Samples of air-dried DCBF prepared according to Example 1 were soaked in PBS at a ratio in a range of about 1:1 DCBF/PBS (g/ml) to about 1:5 DCBF/PBS (g/ml) for 5 to 15 minutes. Sets of samples were prepared using PBS at concentrations of 0.5×, and 0.25× of a standard PBS, using water as the diluent. After the soak, the samples were air-dried on a vacuum sieve, then lyophilized in open jars. The samples were then hydrated with just enough saline to provide good handling properties, and tested for appearance and hydration.
Drops of saline deposited onto the top surface of a low-density pre-formed fiber shape prepared with 0.25×PBS were absorbed in less than one minute. Drops of saline deposited onto the top surface of a low-density pre-formed fiber shape prepared with 0.5×PBS were absorbed more quickly.
Samples of wet DCBF were prepared according to Example 1 without the final drying step. Samples of various sizes were soaked in a standard PBS at a ratio in a range of about 1:2 DCBF/PBS (g/ml) to about 1:5 DCBF/PBS (g/ml) for 5 to 15 minutes. After the soak, the samples were air-dried on a vacuum sieve, deposited in open jars, frozen, then lyophilized. The lyophilized samples were then tested for appearance and hydration. All of the samples had a fluffy appearance.
Low-density pre-formed fiber shapes prepared as described above were hydrated with sheep's blood, and the rates of absorption were compared with those of fiber shapes that had been prepared at a lower DCBF/PBS ratio in a range of about 1:2 (g/ml) and 1:5 (g/ml). Fiber shapes prepared at the higher ratio absorbed the sheep's blood at much faster rates than had been observed for the fiber shapes prepared at the lower ratio. The absorption rate was fastest for fiber shapes prepared at the highest ratio.
Samples of wet DCBF were prepared according to Example 1 without the final drying step. Two portions of wet DCBF were subjected to a static soak in standard PBS at a ratio in a range of about 1:3 DCBF/PBS (g/ml) to about 1:15 DCBF/PBS (g/ml), and air-dried. PBS diluted to 0.5× was added to a first portion at a ratio in a range of about 1:1 DCBF/PBS (g/ml) to about 1:5 DCBF/PBS (g/ml), and the DCBF was lyophilized in a plastic jar. Water was added to the second portion at a ratio in a range of about 1:1 DCBF/PBS (g/ml) to about 1:5 DCBF/PBS (g/ml), and the DCBF was lyophilized in a plastic jar.
Equal amounts of sheep's blood were dropped onto the lyophilized first (PBS) and second (water) portions of DCBF. The blood was entirely absorbed by the first portion within less than one minute, at which time only about one-third (⅓) of the blood was absorbed by the second portion.
Samples of wet DCBF are prepared according to Example 1 without the final drying step. Mineralized granules or chips of cortical or cancellous bone having sizes in a range of about 200 μm to about 5 mm are prepared by milling or cutting of bone tissue which has been cleaned of any soft tissue adhering to the bone and treated with detergents/surfactants to remove blood and lipids. Following separate air-drying steps on individual vacuum sieves, mineralized cortical or cancellous granules/chips and DCBF are mixed in standard PBS at a ratio in a range of about 1:3 DCBF/PBS (g/ml) to about 1:15 DCBF/PBS (g/ml). The ratio of cortical or cancellous granules/chips to DCBF is in a range of about 1:0.1 to about 0.1:1 (g/g, based on air-dried weight), depending on the properties desired for the implant.
After mixing to obtain an approximately homogenous mixture, the resulting tissue mixture is air-dried on a vacuum sieve and deposited in jars which are subsequently filled with a volume of 0.5×PBS to re-suspend the tissue in liquid. The jars are sealed using lids with openings covered by porous liners, then frozen and lyophilized. Alternatively, after mixing and air-drying, the semi-wet tissue is placed into molds and lyophilized.
The lyophilized tissue is readily rehydrated with blood or saline and yields a moldable mass of bone tissue in which the cortical fibers provide cohesiveness and depending on their density within the tissue mass, the cortical/cancellous granules provide the implant with properties of radiopacity and/or resistance to compression.
Wet DCBF prepared as in Example 1 was placed into a rectangular mold and shaped into an implant having dimensions of approximately 10 cm×2.5 cm×7 mm. The fiber implant was removed from the mold and placed in a UV containment chamber where it was exposed to 315-400 nm UVA radiation for a period of about 30 minutes at an intensity in a range of about 4,000 μwatts/cm2 to 20,000 μwatts/cm2. The orientation of the implant was changed within the UV chamber during the irradiation process to expose all surfaces of the implant evenly to UV radiation, creating a stiff shell on all surfaces of the implant. The implant was then lyophilized for storage, and rehydrated prior to implantation.
Wet DCBF prepared as in Example 1 is placed into a rectangular mold having silicone inserts to form two large compartments on one surface of the implant. The resulting implant has dimensions of approximately 10 cm×2.5 cm×1.2 mm. The implant is removed from the mold with the silicone inserts in place. The implant is placed in a UV containment chamber where the exposed surfaces are exposed to both 100-280 nm UVC radiation and 315-400 nm UVA radiation. The longer UVA wavelength penetrates deeper into the surfaces of the implant, which imparts additional stiffness allowing the implant to retain its shape when rehydrated and loaded with additional materials in the compartments whereas the shorter UVC wavelength sterilizes the surfaces of the implant. The silicone inserts block the UVC and UVA radiation from reaching the interior of the cavities so that cross-linking does not occur at those surfaces. The resulting “boat” configuration implant has two open compartments that allow the user to add other materials such as bone marrow aspirate and cancellous chips, or other additives such as those discussed in Section III of the present disclosure. The interior surfaces of the compartments are not cross-linked, so that a user can mix the additives (e.g., the bone marrow aspirate and cancellous chips) into the non-cross-linked DCBF. After mixing, the user can pick up the implant in a single piece and fold it so as to close the compartments such that the additives are enclosed within the implant.
Wet DCBF prepared according to Example 1 are placed in a shallow rectangular mold to produce a thin strip-like implant with dimensions of approximately 10 cm×2.5 cm×2 mm. The implant is removed from the mold, and placed in a UV containment chamber where the exposed surfaces are exposed to 315-400 nm UVA radiation. The implant is thin enough that penetration of the UV radiation cross-links the majority of the DCBF in the interior of the implant. The resulting cross-linked implant is a porous and flexible strip that is also strong enough to be placed in areas of the body that are subject to mechanical loads that would disrupt implants having only a cross-linked shell.
Wet DCBF prepared according to Example 1 are placed in a square mold to produce cube-shaped implants having dimensions ranging from about 5 mm to about 20 mm. Excess water is added to the mold to produce implants that are highly porous. The implants are then lyophilized and rehydrated carefully as to not disturb the porous structure. The implants are then placed into a UV containment chamber where the exterior surfaces are exposed to 315-400 nm UVA radiation. The implant is then lyophilized again. The resulting low density implant is highly porous yet is able to absorb liquids without swelling or deforming permanently.
Lyophilized DCBF prepared as in Example 1 was rehydrated and separated into portions. Each portion was placed into a customized cylindrical mold to produce puck-shaped implants. A first group of implants were irradiated with UVA radiation at an intensity in a range of about 4,000 μwatts/cm2 to 20,000 μwatts/cm2. The top and bottom of the first implant were irradiated for 15 minutes each, for a total exposure time of 30 minutes, for a total energy exposure in a range of about 180 Joules to about 900 Joules. The second group of implants were not irradiated, and served as comparison samples. The implants were then lyophilized. The implants had final dimensions of about 13 mm height and 29 mm diameter.
The implants were compared as follows:
1. Implants from the irradiated and non-irradiated groups were immersed in water or in saline solution. The implants from both groups remained intact. The implants from the irradiated group did not swell by any significant amount, but the implants from the non-irradiated group swelled by a considerable amount.
2. Implants from the irradiated and non-irradiated groups were compressed to a fraction of their initial size. Implants from the irradiated group showed better shape memory retention than implants from the non-irradiated group.
3. Rehydration of the lyophilized implants from both groups showed that the irradiated implants absorbed liquids more rapidly than the non-irradiated implants, and retained their shape better after rehydration even after being compressed significantly.
4. A moldability test showed that the irradiated implants became permanently deformed when sufficient pressure was applied to break the outer shell formed by cross-linking. The irradiated implants could then be molded into a variety of shapes.
Lyophilized fibers of articular cartilage, obtained by grating larger cartilage pieces, are rehydrated and placed in a cylindrical mold to produce plug-shaped implants having diameters in a range of about 5 mm to about 40 mm and lengths in a range of about 5 mm-to about 20 mm. The implants are removed from the molds, and placed in a UV containment chamber where the surfaces of the plugs are exposed to 315-400 nm UVA. The implant is then lyophilized and rehydrated. The resulting implant is compressible, but retains its shape when subjected to cyclical loading. The implant also stays in one piece and does not disperse when subjected to a load, during irrigation, or when placed in an aqueous environment.
Lyophilized tissues (e.g., fibers, flakes or powder) derived from placental (amnion, chorion, umbilical cord) or dermal tissue were rehydrated and compressed into thin sheets. The sheets were then trimmed or otherwise formed into a variety of shapes of varying sizes. The sheets were placed in a UV containment chamber where the surfaces of the sheets were exposed to 315-400 nm UVA radiation for about 20 minutes at a radiation intensity of about 20,000 μwatts/cm2. The implant was then lyophilized and rehydrated prior to implantation. The resulting implant was a very thin sheet that retained its shape when flexed, perforated, irrigated, and placed in an aqueous environment.
Wet DCBF prepared as in Example 1 are placed into a rectangular mold and shaped into an implant having dimensions of approximately 10 cm×2.5 cm×7 mm. The fiber implant is removed from the mold and placed in a sealed vapor chamber. A solution of glutaraldehyde is heated within the chamber to generate glutaraldehyde vapors which penetrate and cross-link DCBF throughout the entire implant. The implant is exposed to the vapors for a set amount of time in a range of about 5 minutes to about 24 hours). After cross-linking, the residual unreacted glutaraldehyde and any unbound cross-linking byproducts are rinsed out of the implant using water, solutions of neutralization salts, and/or buffer solutions. The implant is then lyophilized for storage, and rehydrated prior to implantation.
Wet DCBF prepared as in Example 1 are placed into a rectangular mold and shaped into an implant having dimensions of approximately 10 cm×2.5 cm×7 mm. A mesh is placed over the open surface of the mold to allow liquids access to the tissue while preventing the tissue from escaping the mold. The mold is submerged in a solution of genipin for a set amount of time in a range of about 5 minutes to about 24 hours. The genipin solution may remain static or can be stirred to increase the rate of cross-linking throughout the implant. After cross-linking, the residual genipin is rinsed out of the implant using water. Other rinses including detergents, salts, and/or buffers may be used to reduce residual staining of the tissue that occurs during the genipin cross-linking process. The implant is then lyophilized for storage, and rehydrated prior to implantation.
Three grams of lyophilized DCBF was weighed out in a jar and between about 5 to about 7.5 ml of PBS was added to the DCBF. The two components were mixed, capped and let stand for more than 15 minutes at room temperature to ensure full homogenous hydration. The equilibrated mixture was packed into a plastic syringe, which was then capped and sealed in a foil pouch to prevent moisture loss during long-term storage. The mixture was extruded from the syringe into a pan and examined. The mixture was observed to have a slight off-white color, and to have a smooth consistency that held together when manually manipulated.
Wet DCBF prepared as in Example 1 are rolled into a mass and kneaded to loosen any clumps of fibers and create more fiber entanglement throughout the mass. Once thoroughly kneaded, the whole mass is placed into the mold and the tissue is redistributed into the mold space by pressing with fingers or a spatula. The tissue is lyophilized in the mold, creating a shaped implant.
Molding DCBF in this manner results in an implant with enhanced cohesiveness when rehydrated, compared to an implant where tissue is placed into the mold in small chunks.
Use of a syringe mold to shape the DCBF is shown schematically in
As shown in
Wet DCBF prepared as in Example 1 is combined with mineralized cortical or cancellous granules/powder, placed into a rectangular mold, and shaped into an implant having dimensions of approximately 10 cm(L)×2.5 cm(W)×7 mm(H). The implant is removed from the mold and placed in a UV containment chamber where it is exposed to 315-400 nm UVA radiation for a period of about 30 minutes at an intensity in a range of from about 4,000 μwatts/cm2 to about 20,000 μwatts/cm2 before being removed and lyophilized. The inclusion of mineralized cortical or cancellous in the implant imparts additional radio-opacity due to the added mineral content. This allows for improved visualization of the graft by certain imaging methodologies (e.g. x-ray) during or after implantation of the graft material.
Wet DCBF prepared as in Example 1 are placed into a custom cylindrical syringe mold yielding an implant with final dimensions of approximately 13 mm in height and 29 mm in diameter. The implant is removed from the mold and placed in a UV containment chamber where it was exposed to 315-400 nm UVA radiation for a period of about 30 minutes at an intensity in a range of from about 4,000 μwatts/cm2 to about 20,000 μwatts/cm2. The UV irradiation cross-links the outer surface of the implant allowing the implant to retain its shape when submerged in a liquid solution.
To remineralize the implant, two solutions are prepared as follows. The first solution is composed of 0.55M calcium chloride in DI water and the second solution is composed of 0.5M sodium phosphate in DI water. The irradiated implant is fully submerged in an aliquot of the first solution for 30 minutes under gentle agitation. After 30 minutes, the first solution is removed and the implant is submerged in an aliquot of the second solution for 30 minutes under gentle agitation. This process of alternating solutions is repeated until a hard mineralized shell develops on the surface of the implant that imparts radio-opacity that is comparable to normal mineralized human bone and increased mechanical strength of the implant through the remineralization of DCBF. The bulk/interior of the implant may also be mineralized in a similar fashion of alternating soaks of calcium chloride and sodium phosphate by the use of increased agitation and forcing the solutions through the bulk of the implant using positive or negative pressure. The implant is then lyophilized for storage and rehydrated prior to implantation.
Wet DCBF prepared as in Example 1 are combined with minced, powdered, or fibrous periosteum, placed into a rectangular mold, and shaped into an implant having dimensions of approximately 10 cm(L)×2.5 cm(W)×7 mm(H). The implant is removed from the mold and placed in a UV containment chamber where it was exposed to 315-400 nm UVA radiation for a period of about 30 minutes at an intensity in a range of from about 4,000 μwatts/cm2 to about 20,000 μwatts/cm2 before being removed and lyophilized. The inclusion of periosteum in the implant imparts enhanced cohesiveness and irrigation resistance due to the putty-like nature of periosteum and enhanced biological properties due to the addition of growth factors endogenous to the periosteum membrane.
Wet DCBF prepared and molded into a shaped implant as in Examples 18 and 19 are placed in a heated chamber (e.g., lyophilizer, incubator, gravity oven), with or without UV exposure, at temperatures of from about 24° C. to about 70° C., and allowed to incubate for a period of time of from about 10 minutes to about 24 hours. The heating process improves the cohesiveness of the implant and prevents the implant from dispersing when placed in a rehydrating solution (e.g., water, saline, blood). After heating, the implant is lyophilized for storage and rehydrated prior to implantation.
A different syringe mold than that used for Example 19 was used to shape DCBF fiber and is shown schematically in
As shown in
Various implants produced by according to Example 24 were tested for wettability as follows and the results are provided below in Table 1. Differently shaped implants were tested where “bricks” were implants having a generally rectangular cross section, and “half pipes” were implants having a generally “C” shaped cross section.
1. Wettability Evaluation: A drop of 0.9% saline solution (roughly 0.3 cc) is added to the top or bottom surface of the implant and the length of time it takes for each droplet to absorb into the implant is recorded.
2. Rehydration Evaluation: The implant is placed into a basin containing excess 0.9% saline solution to completely submerge the implant. The length of time it takes for the implant to absorb enough liquid to sink to the bottom of the basin is recorded.
3. Wettability/rehydration times utilizing the droplet test range from a few seconds (0:07) to a few minutes (4:00) whereas complete rehydration of the implant varies from 24 seconds to 20 minutes.
4. Preferred/suitable wettability/rehydration times for DCBF implants may be tailored to the end user/application and could range anywhere from near instantaneous wettability/rehydration (1-2 seconds) to much longer rehydration times of upwards of 20-30 min (preferably within 5 min).
Various implants produced by according to Example 24 were tested for uniform densitys follows and the results are provided below in Table 2. Differently shaped implants were tested where a “disc” was an implant having a generally circular cross section, and “strips” were implants having a generally rectangular shaped cross section.
1. The weight of a DCBF implant was measured using an analytical balance.
2. Calipers were used to measure the dimensions of the implant, and the volume of the implant was calculated.
3. The density of the entire implant was calculated by dividing the weight recorded in step 1 by the volume calculated in step 2.
4. The implant was then cut into four equally sized pieces (quarters Q1, Q2, Q3 and Q4) using a scalpel. Steps 1-3 were repeated for each piece of the implant.
5. The relative standard deviation of the densities was calculated by dividing the standard deviation of the densities by the average. An implant can be said to have uniform density if the relative standard deviation of the measured densities is less than about 30%.
While the disclosed invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the described invention.
This application is a divisional of U.S. patent application Ser. No. 15/159,406 filed on May 19, 2016, now allowed and which claims the benefit of U.S. Provisional Application No. 62/331,071, filed May 3, 2016, and U.S. Provisional Application No. 62/164,827, filed May 21, 2015, the entire disclosures of all of which are incorporated by reference herein. This application also relates to commonly owned International Application No. PCT/US16/33246, filed May 19, 2016 and entitled “Modified Demineralized Cortical Bone Fibers,” the entire disclosure of which is incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 753155 | MacFarlane | Feb 1904 | A |
| 2446573 | Cameron | Aug 1948 | A |
| 3856219 | Stayton et al. | Dec 1974 | A |
| 4294753 | Urist | Oct 1981 | A |
| 4361552 | Baur | Nov 1982 | A |
| 4394370 | Jefferies | Jul 1983 | A |
| 4627853 | Campbell | Dec 1986 | A |
| 4820626 | Williams et al. | Apr 1989 | A |
| 5002071 | Harrell | Mar 1991 | A |
| 5035708 | Alchas | Jul 1991 | A |
| 5061286 | Lyle | Oct 1991 | A |
| 5073373 | O'Leary | Dec 1991 | A |
| 5079160 | Lacy | Jan 1992 | A |
| 5112354 | Sires | May 1992 | A |
| 5131907 | Williams | Jul 1992 | A |
| 5204319 | Enomoto | Apr 1993 | A |
| 5219576 | Chu | Jun 1993 | A |
| 5230693 | Williams | Jul 1993 | A |
| 5236456 | O'Leary | Aug 1993 | A |
| 5275954 | Wolfinbarger et al. | Jan 1994 | A |
| 5284655 | Bogdansky et al. | Feb 1994 | A |
| 5290558 | O'Leary | Mar 1994 | A |
| 5298254 | Prewell | Mar 1994 | A |
| 5314476 | Prewett et al. | May 1994 | A |
| 5333626 | Morse | Aug 1994 | A |
| 5356629 | Sander et al. | Oct 1994 | A |
| 5405390 | O'Leary et al. | Apr 1995 | A |
| 5439684 | Prewell | Aug 1995 | A |
| 5484601 | O'Leary et al. | Jan 1996 | A |
| 5486359 | Caplan | Jan 1996 | A |
| 5507813 | Dowd | Apr 1996 | A |
| 5510396 | Prewett et al. | Apr 1996 | A |
| 5513662 | Morse | May 1996 | A |
| 5556379 | Wolfinbarger | Sep 1996 | A |
| 5573771 | Geistlich et al. | Nov 1996 | A |
| 5607269 | Dowd et al. | Mar 1997 | A |
| 5612028 | Sackler | Mar 1997 | A |
| 5628781 | Williams | May 1997 | A |
| 5676146 | Scarborough | Oct 1997 | A |
| 5700289 | Breibart | Dec 1997 | A |
| 5702677 | Shimp et al. | Dec 1997 | A |
| 5707962 | Chen et al. | Jan 1998 | A |
| 5744360 | Hu | Apr 1998 | A |
| 5797871 | Wolfinbarger | Aug 1998 | A |
| 5804366 | Hu | Sep 1998 | A |
| 5807275 | Jamshidi | Sep 1998 | A |
| 5824078 | Nelson | Oct 1998 | A |
| 5824084 | Muschler | Oct 1998 | A |
| 5830493 | Yokota et al. | Nov 1998 | A |
| 5837235 | Mueller | Nov 1998 | A |
| 5842477 | Naughton | Dec 1998 | A |
| 5869037 | Crystal | Feb 1999 | A |
| 5895426 | Scarborough et al. | Apr 1999 | A |
| 5899939 | Boyce | May 1999 | A |
| 5904718 | Jeffries | May 1999 | A |
| 5918821 | Grooms et al. | Jul 1999 | A |
| 5968556 | Atala et al. | Oct 1999 | A |
| 5980948 | Goedemoed et al. | Nov 1999 | A |
| 6020196 | Hu | Feb 2000 | A |
| 6030635 | Gertzman et al. | Feb 2000 | A |
| 6045580 | Scarborough et al. | Apr 2000 | A |
| 6049026 | Muschler | Apr 2000 | A |
| 6051750 | Bell | Apr 2000 | A |
| 6077987 | Breitbart | Jun 2000 | A |
| 6123731 | Boyce | Sep 2000 | A |
| 6149906 | Mosca | Nov 2000 | A |
| 6152142 | Tseng | Nov 2000 | A |
| 6162258 | Scarborough et al. | Dec 2000 | A |
| 6180605 | Chen et al. | Jan 2001 | B1 |
| 6180606 | Chen et al. | Jan 2001 | B1 |
| 6187053 | Minuth | Feb 2001 | B1 |
| 6189537 | Wolfinbarger | Feb 2001 | B1 |
| 6326019 | Tseng | Feb 2001 | B1 |
| 6284284 | Naughton | Sep 2001 | B1 |
| 6293970 | Wolfinbarger et al. | Sep 2001 | B1 |
| 6294041 | Boyce et al. | Sep 2001 | B1 |
| 6294187 | Boyce | Sep 2001 | B1 |
| 6305379 | Wolfinbarger | Oct 2001 | B1 |
| 6309659 | Clokie | Oct 2001 | B1 |
| 6311690 | Jefferies | Nov 2001 | B1 |
| 6312952 | Hicks | Nov 2001 | B1 |
| 6315795 | Scarborough et al. | Nov 2001 | B1 |
| 6316247 | Katz | Nov 2001 | B1 |
| 6326018 | Gertzman | Dec 2001 | B1 |
| 6332779 | Boyce | Dec 2001 | B1 |
| 6340477 | Anderson | Jan 2002 | B1 |
| 6348069 | Vacanti | Feb 2002 | B1 |
| 6350283 | Michelson | Feb 2002 | B1 |
| 6355239 | Bruder | Mar 2002 | B1 |
| 6372257 | Marchosky | Apr 2002 | B1 |
| 6375663 | Ebner | Apr 2002 | B1 |
| 6376244 | Atala | Apr 2002 | B1 |
| 6379371 | Novak | Apr 2002 | B1 |
| 6387693 | Reiser | May 2002 | B2 |
| 6391297 | Halvorsen | May 2002 | B1 |
| 6398819 | Bell | Jun 2002 | B1 |
| 6413278 | Marchosky | Jul 2002 | B1 |
| 6425949 | Lemaire et al. | Jul 2002 | B1 |
| 6429013 | Halvorsen | Aug 2002 | B1 |
| 6432436 | Gertzman et al. | Aug 2002 | B1 |
| 6436138 | Dowd | Aug 2002 | B1 |
| 6437018 | Gertzman et al. | Aug 2002 | B1 |
| 6440444 | Boyce | Aug 2002 | B2 |
| 6458375 | Gertzman | Oct 2002 | B1 |
| 6461632 | Gogolewski | Oct 2002 | B1 |
| 6465205 | Hicks, Jr. | Oct 2002 | B2 |
| 6478825 | Winterbottom | Nov 2002 | B1 |
| 6484954 | Lenox | Nov 2002 | B2 |
| 6534095 | Moore-Smith | Mar 2003 | B1 |
| 6548080 | Gertzman et al. | Apr 2003 | B1 |
| 6565884 | Nimmi | May 2003 | B2 |
| 6569200 | Wolfinbarger et al. | May 2003 | B2 |
| 6576015 | Geistlich et al. | Jun 2003 | B2 |
| 6576249 | Gendler | Jun 2003 | B1 |
| 6596274 | Abatangelo | Jul 2003 | B1 |
| 6599520 | Scarborough | Jul 2003 | B2 |
| 6616698 | Scarborough | Sep 2003 | B2 |
| 6620196 | Trieu | Sep 2003 | B1 |
| 6623748 | Clokie | Sep 2003 | B2 |
| 6630153 | Long et al. | Oct 2003 | B2 |
| 6625593 | Boyer | Nov 2003 | B1 |
| 6652592 | Grooms et al. | Nov 2003 | B1 |
| 6652872 | Nevo | Nov 2003 | B2 |
| 6652887 | Richelsophe et al. | Nov 2003 | B1 |
| 6660038 | Boyer | Dec 2003 | B2 |
| 6685626 | Wironen | Feb 2004 | B2 |
| 6696073 | Boyce | Feb 2004 | B2 |
| 6706067 | Shimp | Mar 2004 | B2 |
| 6723131 | Muschler | Apr 2004 | B2 |
| RE38522 | Gertman et al. | May 2004 | E |
| 6749636 | Michelson | Jun 2004 | B2 |
| 6752831 | Sybert | Jun 2004 | B2 |
| 6755365 | Meredith et al. | Jun 2004 | B1 |
| 6776800 | Boyer | Aug 2004 | B2 |
| 6777231 | Katz | Aug 2004 | B1 |
| 6808585 | Boyce | Oct 2004 | B2 |
| 6830763 | O'Leary et al. | Dec 2004 | B2 |
| 6837907 | Wolfinbarger et al. | Jan 2005 | B2 |
| 6841150 | Halvorsen | Jan 2005 | B2 |
| 6843807 | Boyce et al. | Jan 2005 | B1 |
| 6846853 | Shimp | Jan 2005 | B2 |
| 6855169 | Boyer, II et al. | Feb 2005 | B2 |
| 6863694 | Boyce | Mar 2005 | B1 |
| 6893466 | Trieu | May 2005 | B2 |
| 6899107 | Lewandrowski | May 2005 | B2 |
| 6911212 | Gertzman et al. | Jun 2005 | B2 |
| 6974862 | Ringeisen et al. | Dec 2005 | B2 |
| 6979307 | Beretta | Dec 2005 | B2 |
| 6979679 | Marcum | Dec 2005 | B2 |
| 6991652 | Burg | Jan 2006 | B2 |
| 6998135 | Sunwoo et al. | Feb 2006 | B1 |
| 7004977 | Ashman | Feb 2006 | B2 |
| 7005136 | Nathan et al. | Feb 2006 | B2 |
| 7008591 | Kafesjian | Mar 2006 | B2 |
| 7008763 | Cheung | Mar 2006 | B2 |
| 7019192 | Gertzman et al. | Mar 2006 | B2 |
| 7029666 | Bruder | Apr 2006 | B2 |
| 7029689 | Berglund | Apr 2006 | B2 |
| 7029838 | Williams | Apr 2006 | B2 |
| 7033587 | Halvorsen | Apr 2006 | B2 |
| 7045141 | Merboth et al. | May 2006 | B2 |
| 7052829 | Williams | May 2006 | B2 |
| 7052907 | Shi | May 2006 | B2 |
| 7063726 | Crouch et al. | Jun 2006 | B2 |
| 7067123 | Gomes et al. | Jun 2006 | B2 |
| 7078230 | Wilkison | Jul 2006 | B2 |
| 7078232 | Konkle | Jul 2006 | B2 |
| 7148036 | Luyten | Dec 2006 | B2 |
| 7153518 | Wironen et al. | Dec 2006 | B2 |
| 7163691 | Knaack | Jan 2007 | B2 |
| 7166133 | Evans | Jan 2007 | B2 |
| 7172629 | McKay | Feb 2007 | B2 |
| 7179299 | Edwards | Feb 2007 | B2 |
| 7186557 | Marko | Mar 2007 | B2 |
| 7189392 | Kim et al. | Mar 2007 | B1 |
| RE39587 | Gertzman et al. | Apr 2007 | E |
| 7201917 | Malaviya | Apr 2007 | B2 |
| 7214765 | Ringeisen et al. | May 2007 | B2 |
| 7241316 | Evans | Jul 2007 | B2 |
| 7244444 | Bales | Jul 2007 | B2 |
| 7250550 | Overby et al. | Jul 2007 | B2 |
| 7255879 | Hariri | Aug 2007 | B2 |
| 7270813 | Shimp et al. | Sep 2007 | B2 |
| 7273756 | Adkisson | Sep 2007 | B2 |
| 7291179 | Miller et al. | Nov 2007 | B2 |
| 7291345 | Winterbottom et al. | Nov 2007 | B2 |
| 7294509 | Darimont | Nov 2007 | B2 |
| 7297540 | Miltrani | Nov 2007 | B2 |
| 7311904 | Haran | Dec 2007 | B2 |
| 7311905 | Hariri | Dec 2007 | B2 |
| 7323190 | Chu | Jan 2008 | B2 |
| 7323193 | Morris | Jan 2008 | B2 |
| 7326571 | Freyman | Feb 2008 | B2 |
| 7335381 | Malinin | Feb 2008 | B2 |
| 7347876 | Tsai | Mar 2008 | B2 |
| 7390484 | Fraser | Jun 2008 | B2 |
| 7413576 | Sybert | Aug 2008 | B2 |
| 7413734 | Mistry | Aug 2008 | B2 |
| 7416889 | Ciombor | Aug 2008 | B2 |
| 7429488 | Fraser | Sep 2008 | B2 |
| 7445793 | Niwa | Nov 2008 | B2 |
| 7459307 | Ha | Dec 2008 | B2 |
| 7468242 | Bellomo | Dec 2008 | B2 |
| 7468276 | Harin | Dec 2008 | B2 |
| 7470537 | Hedrick | Dec 2008 | B2 |
| 7473420 | Fraser | Jan 2009 | B2 |
| 7473678 | Lynch | Jan 2009 | B2 |
| 7476257 | Sah | Jan 2009 | B2 |
| 7485629 | Marcum | Feb 2009 | B2 |
| 7488348 | Truncale | Feb 2009 | B2 |
| 7494802 | Tseng | Feb 2009 | B2 |
| 7494811 | Wolfinbarger et al. | Feb 2009 | B2 |
| 7494950 | Armiage et al. | Feb 2009 | B2 |
| 7498040 | Masinaei | Mar 2009 | B2 |
| 7498041 | Masinaei | Mar 2009 | B2 |
| 7498171 | Hariri et al. | Mar 2009 | B2 |
| 7501115 | Fraser | Mar 2009 | B2 |
| 7503936 | Trieu | Mar 2009 | B2 |
| 7504387 | Marcum | Mar 2009 | B2 |
| 7514075 | Hedrick | Apr 2009 | B2 |
| 7524489 | Messina | Apr 2009 | B2 |
| 7531355 | Rodriquez et al. | May 2009 | B2 |
| 7537617 | Bindsell | May 2009 | B2 |
| 7560276 | Harmon | Jul 2009 | B2 |
| 7563455 | McKay | Jul 2009 | B2 |
| 7575743 | Hunziker | Aug 2009 | B2 |
| 7582292 | Wilkison et al. | Sep 2009 | B2 |
| 7582309 | Rosenberg et al. | Sep 2009 | B2 |
| 7585670 | Hedrick | Sep 2009 | B2 |
| 7592174 | Sylvester | Sep 2009 | B2 |
| 7595043 | Hedrick | Sep 2009 | B2 |
| 7595062 | Pedrozo | Sep 2009 | B2 |
| 7608113 | Boyer | Oct 2009 | B2 |
| 7608580 | Kim et al. | Oct 2009 | B2 |
| 7618461 | Trieu | Nov 2009 | B2 |
| 7621963 | Simon | Nov 2009 | B2 |
| 7628851 | Armitage et al. | Dec 2009 | B2 |
| 7637872 | Fox | Dec 2009 | B1 |
| 7651684 | Hedrick | Jan 2010 | B2 |
| 2042010 | Clarke | Feb 2010 | A1 |
| 7655010 | Serhan et al. | Feb 2010 | B2 |
| 7658768 | Miller et al. | Feb 2010 | B2 |
| 7662184 | Edwards | Feb 2010 | B2 |
| 7670384 | Kumar | Mar 2010 | B2 |
| 7675272 | Michallick et al. | Mar 2010 | B2 |
| 7678385 | Reddi | Mar 2010 | B2 |
| 7682803 | Paludan | Mar 2010 | B2 |
| 7687059 | Fraser | Mar 2010 | B2 |
| 7709018 | Pastorello | May 2010 | B2 |
| 7726319 | Boyce | Jun 2010 | B1 |
| 7732126 | Zhang | Jun 2010 | B2 |
| 7744597 | Gaskins | Jun 2010 | B2 |
| 7745106 | Beretta | Jun 2010 | B2 |
| 7753963 | Boyce | Jul 2010 | B2 |
| 7766972 | Overby et al. | Aug 2010 | B2 |
| 7767452 | Kleinsek | Aug 2010 | B2 |
| 7771716 | Hedrick | Aug 2010 | B2 |
| 7772209 | Niyikiza | Aug 2010 | B2 |
| 7775965 | McFedrige | Aug 2010 | B2 |
| 7776596 | Badylak | Aug 2010 | B2 |
| 7785582 | Johnson | Aug 2010 | B2 |
| 7785634 | Borden | Aug 2010 | B2 |
| 7795022 | Badylak | Sep 2010 | B2 |
| 7795027 | Miles | Sep 2010 | B2 |
| 7799076 | Sybert | Sep 2010 | B2 |
| 7799767 | Lamberti et al. | Sep 2010 | B2 |
| 7807461 | Kang | Oct 2010 | B2 |
| 7815686 | Badylak | Oct 2010 | B2 |
| 7824671 | Binder | Nov 2010 | B2 |
| 7824702 | Wironen et al. | Nov 2010 | B2 |
| 7824703 | Scifert et al. | Nov 2010 | B2 |
| 7833278 | Evans | Nov 2010 | B2 |
| 7833968 | Soo et al. | Nov 2010 | B2 |
| 7837708 | Schmieding | Nov 2010 | B2 |
| 7842300 | Atkinson et al. | Nov 2010 | B2 |
| 7846728 | Brooks | Dec 2010 | B2 |
| 7854923 | Chen et al. | Dec 2010 | B2 |
| 7858296 | Sowmino-Coker | Dec 2010 | B2 |
| 7871646 | Ghinelli | Jan 2011 | B2 |
| 7875272 | Messina | Jan 2011 | B2 |
| 7875273 | Messina | Jan 2011 | B2 |
| 7875296 | Binette | Jan 2011 | B2 |
| 7887795 | Fraser | Feb 2011 | B2 |
| 7888119 | Sugaya | Feb 2011 | B2 |
| 7892577 | Borden | Feb 2011 | B2 |
| RE42208 | Truncale et al. | Mar 2011 | E |
| 7901457 | Truncale et al. | Mar 2011 | B2 |
| 7901461 | Harmon | Mar 2011 | B2 |
| 7901672 | Fraser | Mar 2011 | B2 |
| 7906110 | Chancellor | Mar 2011 | B2 |
| 7910690 | Ringeisen et al. | Mar 2011 | B2 |
| 7914779 | Hariri | Mar 2011 | B2 |
| 7915039 | Teplyashin | Mar 2011 | B2 |
| 7923246 | Sasai | Apr 2011 | B2 |
| 7931687 | Masuda | Apr 2011 | B2 |
| 7931692 | Sybert et al. | Apr 2011 | B2 |
| 7932084 | Katz | Apr 2011 | B2 |
| 7939092 | McKay et al. | May 2011 | B2 |
| 7939108 | Morris | May 2011 | B2 |
| 7947266 | Grothos | May 2011 | B2 |
| 7951200 | Heinz | May 2011 | B2 |
| 7955616 | Kroenentha | Jun 2011 | B2 |
| 7959683 | Semler et al. | Jun 2011 | B2 |
| 7959941 | Knaack | Jun 2011 | B2 |
| 7968329 | Dancu | Jun 2011 | B2 |
| 7977094 | Masinaei | Jul 2011 | B2 |
| 7998472 | Huss | Aug 2011 | B2 |
| 7998735 | Morrison | Aug 2011 | B2 |
| 8002813 | Scarborough | Aug 2011 | B2 |
| 8002843 | Knacck | Aug 2011 | B2 |
| 8039016 | Drapeau | Oct 2011 | B2 |
| 8053423 | Lamberti et al. | Nov 2011 | B2 |
| 8057595 | Armitage et al. | Nov 2011 | B2 |
| 8101676 | McKay | Jan 2012 | B2 |
| 8105383 | Michelson | Jan 2012 | B2 |
| 8106008 | Lynch | Jan 2012 | B2 |
| RE43258 | Truncale et al. | Mar 2012 | E |
| 8133421 | Boyce | Mar 2012 | B2 |
| 8133500 | Ringeisen | Mar 2012 | B2 |
| 8137403 | Michelson | Mar 2012 | B2 |
| 8137408 | Kadiyala | Mar 2012 | B2 |
| 8137686 | Kladakis | Mar 2012 | B2 |
| 8147862 | McKay | Apr 2012 | B2 |
| 8153612 | Ben-Shalom et al. | Apr 2012 | B2 |
| 8182532 | Anderson et al. | May 2012 | B2 |
| 8183229 | Hahn et al. | May 2012 | B2 |
| 8188229 | Ringeisen et al. | May 2012 | B2 |
| 8197474 | Scarborough | Jun 2012 | B2 |
| 8202539 | Benham | Jun 2012 | B2 |
| 8221500 | Truncale et al. | Jul 2012 | B2 |
| 8221781 | Rosenberg et al. | Jul 2012 | B2 |
| 8268008 | Betz | Sep 2012 | B2 |
| 8282953 | Drapeau | Oct 2012 | B2 |
| 8292957 | Michelson | Oct 2012 | B2 |
| 8292968 | Truncale | Oct 2012 | B2 |
| 8309106 | Masinaei | Nov 2012 | B2 |
| 8309131 | Kronenthal | Nov 2012 | B2 |
| 8313742 | Kadiyala et al. | Nov 2012 | B2 |
| 8323700 | Morris et al. | Dec 2012 | B2 |
| 8328876 | Behnam et al. | Dec 2012 | B2 |
| 8333985 | Knaack et al. | Dec 2012 | B2 |
| 8357384 | Behnam | Jan 2013 | B2 |
| 8399010 | McKay | Mar 2013 | B2 |
| 8399409 | Lynch et al. | Mar 2013 | B2 |
| 8419802 | Evans | Apr 2013 | B2 |
| 8425619 | Evans et al. | Apr 2013 | B2 |
| 8454988 | Rosenberg | Jun 2013 | B2 |
| 8455458 | Marcum | Jun 2013 | B2 |
| 8460680 | Williams | Jun 2013 | B2 |
| 8470369 | Marchosky | Jun 2013 | B2 |
| 8475824 | McKay | Jul 2013 | B2 |
| 8496970 | Binette | Jul 2013 | B2 |
| 8513217 | Chen et al. | Aug 2013 | B2 |
| 8524253 | Kinnane | Sep 2013 | B2 |
| 8529862 | Tennent | Sep 2013 | B2 |
| 8529962 | Morris et al. | Sep 2013 | B2 |
| 8545864 | Morris et al. | Oct 2013 | B2 |
| 8551170 | Lacza et al. | Oct 2013 | B2 |
| 8563040 | Marchosky | Oct 2013 | B2 |
| 8574825 | Shelby et al. | Nov 2013 | B2 |
| 8603184 | Rizzoli et al. | Dec 2013 | B2 |
| 8623094 | Evans | Jan 2014 | B2 |
| 8633299 | Ringeisen et al. | Jan 2014 | B2 |
| 8642061 | Shimp et al. | Feb 2014 | B2 |
| 8652503 | Wironen et al. | Feb 2014 | B2 |
| 8658197 | Scifert | Feb 2014 | B2 |
| 8658217 | McKay | Feb 2014 | B2 |
| 8663672 | Manrique | Mar 2014 | B2 |
| 8664202 | Lamberti et al. | Mar 2014 | B2 |
| 8697107 | Drapeau et al. | Apr 2014 | B2 |
| 8697114 | Scifert | Apr 2014 | B2 |
| 8734525 | Behnam | May 2014 | B2 |
| 8734835 | McKay et al. | May 2014 | B2 |
| 8740987 | Geremakis et al. | Jun 2014 | B2 |
| 8747467 | Mills et al. | Jun 2014 | B2 |
| 8753689 | Morris et al. | Jun 2014 | B2 |
| 8758792 | Behnam et al. | Jun 2014 | B2 |
| 8790920 | Freyman | Jun 2014 | B2 |
| 8771368 | McKay | Jul 2014 | B2 |
| 8784499 | Owens et al. | Jul 2014 | B2 |
| 8790681 | Altschuler | Jul 2014 | B2 |
| 8834928 | Truncale et al. | Sep 2014 | B1 |
| 8871742 | Marcum et al. | Oct 2014 | B2 |
| 8876532 | Atkinso et al. | Nov 2014 | B2 |
| 8877221 | McKay | Nov 2014 | B2 |
| 8883210 | Truncale et al. | Nov 2014 | B1 |
| 8926710 | McKay | Jan 2015 | B2 |
| 8957050 | Lamberti et al. | Feb 2015 | B2 |
| 8992628 | Drapeau et al. | Mar 2015 | B2 |
| 9005646 | Masinaei et al. | Apr 2015 | B2 |
| 9034348 | Shalom et al. | May 2015 | B2 |
| 9034644 | Masinei et al. | May 2015 | B2 |
| 9050390 | Rizzoli et al. | Jun 2015 | B2 |
| 9056151 | Lauritzen et al. | Jun 2015 | B2 |
| 9080141 | Wolfingarger et al. | Jul 2015 | B2 |
| 9101606 | Drapeau et al. | Aug 2015 | B2 |
| 9107983 | McKay | Aug 2015 | B2 |
| 9132208 | Chen et al. | Sep 2015 | B2 |
| 9138509 | Sunwoo et al. | Sep 2015 | B2 |
| 9162012 | Benham et al. | Oct 2015 | B2 |
| 9211359 | McKay et al. | Dec 2015 | B2 |
| 9254301 | Marchosky | Feb 2016 | B2 |
| 9259434 | Chen et al. | Feb 2016 | B2 |
| 9265830 | Mossaad et al. | Feb 2016 | B2 |
| 9283074 | Evans et al. | Mar 2016 | B2 |
| 9289452 | Shi | Mar 2016 | B2 |
| 9314545 | Tofighi et al. | Apr 2016 | B2 |
| 9320708 | Scifert | Apr 2016 | B2 |
| 9333276 | Guelcher et al. | May 2016 | B2 |
| 9352003 | Semler et al. | May 2016 | B1 |
| 9364583 | McKay | Jun 2016 | B2 |
| 9375315 | Forsell | Jun 2016 | B2 |
| 9387094 | Manrique et al. | Jun 2016 | B2 |
| 9381211 | Marcum et al. | Jul 2016 | B2 |
| 9393116 | Betz | Jul 2016 | B2 |
| 9408875 | Masinaei et al. | Aug 2016 | B2 |
| 9415139 | Benedict et al. | Aug 2016 | B2 |
| 9480567 | McKay | Nov 2016 | B2 |
| 9486500 | McKay | Nov 2016 | B2 |
| 9486556 | Shi | Nov 2016 | B2 |
| 9486557 | Carter et al. | Nov 2016 | B2 |
| 9511115 | Soo et al. | Dec 2016 | B2 |
| 9554920 | Wei et al. | Jan 2017 | B2 |
| 9572911 | Muir | Feb 2017 | B2 |
| 9572912 | Scarborough et al. | Feb 2017 | B2 |
| 9579416 | Ringeisen et al. | Feb 2017 | B2 |
| 9579421 | Bhat et al. | Feb 2017 | B2 |
| 9623146 | Lamberti et al. | Apr 2017 | B2 |
| 9623153 | McKay | Apr 2017 | B2 |
| 9636436 | Carter et al. | May 2017 | B2 |
| 9682172 | Drapeau et al. | Jun 2017 | B2 |
| 9717822 | Behnam et al. | Aug 2017 | B2 |
| 9730801 | McKay | Aug 2017 | B2 |
| 9731044 | Chen et al. | Aug 2017 | B2 |
| 9775862 | Wei et al. | Oct 2017 | B2 |
| 9801946 | Guelcher et al. | Oct 2017 | B2 |
| 9839722 | McKay | Dec 2017 | B2 |
| 9849215 | Mossaad et al. | Dec 2017 | B2 |
| 9907882 | McKay | Mar 2018 | B2 |
| 9913676 | Schlacter et al. | Mar 2018 | B2 |
| 9956313 | Tofighi et al. | May 2018 | B2 |
| 9962467 | Masinaei et al. | May 2018 | B2 |
| 9981061 | Evans et al. | May 2018 | B2 |
| 9987138 | McKay | Jun 2018 | B2 |
| 9999520 | Manrique et al. | Jun 2018 | B2 |
| 10130736 | Semler et al. | Nov 2018 | B1 |
| 10194964 | Schlachter et al. | Feb 2019 | B2 |
| 20010016703 | Wironen et al. | Aug 2001 | A1 |
| 20010033834 | Wilkison | Oct 2001 | A1 |
| 20010037091 | Wironen et al. | Nov 2001 | A1 |
| 20010041792 | Donda | Nov 2001 | A1 |
| 20020029045 | Bonutti | Mar 2002 | A1 |
| 20020076395 | Crystal | Jun 2002 | A1 |
| 20020076400 | Katz | Jun 2002 | A1 |
| 20020091447 | Shimp | Jul 2002 | A1 |
| 20020106393 | Bianchi et al. | Aug 2002 | A1 |
| 20020107429 | Wironen | Aug 2002 | A1 |
| 20020110544 | Goldberg | Aug 2002 | A1 |
| 20020122790 | Hunziker | Sep 2002 | A1 |
| 20020159982 | Bonassar | Oct 2002 | A1 |
| 20020192263 | Merboth et al. | Dec 2002 | A1 |
| 20030009235 | Manrique et al. | Jan 2003 | A1 |
| 20030054331 | Fraser | Mar 2003 | A1 |
| 20030055511 | Schryer et al. | Mar 2003 | A1 |
| 20030077825 | Bhatnagar | Apr 2003 | A1 |
| 20030082152 | Hedrick | May 2003 | A1 |
| 20030091543 | Klein | May 2003 | A1 |
| 20030113813 | Heidaran | Jun 2003 | A1 |
| 20030147860 | Marchosky | Aug 2003 | A1 |
| 20030148510 | Mitrani | Aug 2003 | A1 |
| 20030152558 | Luft | Aug 2003 | A1 |
| 20030161816 | Fraser | Aug 2003 | A1 |
| 20030162707 | Fraser | Aug 2003 | A1 |
| 20030180262 | Wiroenen et al. | Sep 2003 | A1 |
| 20030180269 | Hariri | Sep 2003 | A1 |
| 20030180344 | Wise et al. | Sep 2003 | A1 |
| 20030181978 | Brown | Sep 2003 | A1 |
| 20030187515 | Hariri | Oct 2003 | A1 |
| 20030206937 | Gertzman | Nov 2003 | A1 |
| 20030224518 | Adkisson | Dec 2003 | A1 |
| 20030228288 | Scarborough et al. | Dec 2003 | A1 |
| 20030235580 | Zhang | Dec 2003 | A1 |
| 20030236573 | Evans et al. | Dec 2003 | A1 |
| 20040002558 | McKay | Jan 2004 | A1 |
| 20040010320 | Huckle | Jan 2004 | A1 |
| 20040028660 | Hariri | Feb 2004 | A1 |
| 20040030406 | Ochi | Feb 2004 | A1 |
| 20040048375 | Alt | Mar 2004 | A1 |
| 20040048796 | Hariri | Mar 2004 | A1 |
| 20040052768 | Morrison | Mar 2004 | A1 |
| 20040057938 | Ghinelli | Mar 2004 | A1 |
| 20040059364 | Gaskin | Mar 2004 | A1 |
| 20040064193 | Evans et al. | Apr 2004 | A1 |
| 20040067218 | Casteilla | Apr 2004 | A1 |
| 20040077079 | Storgaard | Apr 2004 | A1 |
| 20040078077 | Binette | Apr 2004 | A1 |
| 20040078090 | Binette | Apr 2004 | A1 |
| 20040082063 | Deshpande | Apr 2004 | A1 |
| 20040091462 | Lin | May 2004 | A1 |
| 20040092011 | Wilkison | May 2004 | A1 |
| 20040096430 | Bauer | May 2004 | A1 |
| 20040096431 | Fraser | May 2004 | A1 |
| 20040097867 | Fraser | May 2004 | A1 |
| 20040115172 | Bianchi | Jun 2004 | A1 |
| 20040126878 | Ramos | Jul 2004 | A1 |
| 20040127987 | Evans | Jul 2004 | A1 |
| 20040166096 | Kolkin | Aug 2004 | A1 |
| 20040171146 | Katz | Sep 2004 | A1 |
| 20040181240 | Tseng | Sep 2004 | A1 |
| 20040191226 | Badylak | Sep 2004 | A1 |
| 20040197367 | Rezania | Oct 2004 | A1 |
| 20040197373 | Gertzman et al. | Oct 2004 | A1 |
| 20040229351 | Rodriguez | Nov 2004 | A1 |
| 20040230303 | Truncale et al. | Nov 2004 | A1 |
| 20040230309 | DiMauro et al. | Nov 2004 | A1 |
| 20040241146 | Biscup | Dec 2004 | A1 |
| 20040249463 | Bindsell | Dec 2004 | A1 |
| 20040265971 | Sato | Dec 2004 | A1 |
| 20040267362 | Hwang | Dec 2004 | A1 |
| 20050002910 | Wolfingarger | Jan 2005 | A1 |
| 20050003532 | Nakamura | Jan 2005 | A1 |
| 20050008626 | Fraser | Jan 2005 | A1 |
| 20050009000 | Wilhelm | Jan 2005 | A1 |
| 20050019908 | Hariri | Jan 2005 | A1 |
| 20050025755 | Hedrick | Feb 2005 | A1 |
| 20050026279 | Tsent | Feb 2005 | A1 |
| 20050033449 | Ashman | Feb 2005 | A1 |
| 20050048033 | Fraser | Mar 2005 | A1 |
| 20050048034 | Fraser | Mar 2005 | A1 |
| 20050048035 | Fraser | Mar 2005 | A1 |
| 20050048036 | Hedrick | Mar 2005 | A1 |
| 20050048644 | Hedrick | Mar 2005 | A1 |
| 20050058360 | Harris | Mar 2005 | A1 |
| 20050058629 | Harmon | Mar 2005 | A1 |
| 20050058631 | Kihm | Mar 2005 | A1 |
| 20050058632 | Hedrick | Mar 2005 | A1 |
| 20050064041 | O'leary | Mar 2005 | A1 |
| 20050074436 | Fraser | Apr 2005 | A1 |
| 20050076396 | Katz | Apr 2005 | A1 |
| 20050084961 | Hedrick | Apr 2005 | A1 |
| 20050095228 | Fraser | May 2005 | A1 |
| 20050100555 | Pitzalis | May 2005 | A1 |
| 20050112761 | Halvorsen | May 2005 | A1 |
| 20050118228 | Trieu | Jun 2005 | A1 |
| 20050125077 | Harmon | Jun 2005 | A1 |
| 20050136042 | Betz | Jun 2005 | A1 |
| 20050147642 | Laredo | Jul 2005 | A1 |
| 20050147959 | Frondoza | Jul 2005 | A1 |
| 20050152941 | Hunter | Jul 2005 | A1 |
| 20050152944 | Hunter | Jul 2005 | A1 |
| 20050152945 | Hunter | Jul 2005 | A1 |
| 20050152947 | Hunter | Jul 2005 | A1 |
| 20050152948 | Hunter | Jul 2005 | A1 |
| 20050153441 | Hedrick | Jul 2005 | A1 |
| 20050153442 | Katz | Jul 2005 | A1 |
| 20050154463 | Trieu | Jul 2005 | A1 |
| 20050181973 | Genove | Aug 2005 | A1 |
| 20050182463 | Hunter | Aug 2005 | A1 |
| 20050182496 | Hunter | Aug 2005 | A1 |
| 20050187639 | Hunter | Aug 2005 | A1 |
| 20050203635 | Hunter | Sep 2005 | A1 |
| 20050209705 | Niederauer | Sep 2005 | A1 |
| 20050214259 | Sano | Sep 2005 | A1 |
| 20050244239 | Shimp | Nov 2005 | A1 |
| 20050250202 | March | Nov 2005 | A1 |
| 20050255588 | Young | Nov 2005 | A1 |
| 20050260174 | Fraser | Nov 2005 | A1 |
| 20050260175 | Hedrick | Nov 2005 | A1 |
| 20050260748 | Chang | Nov 2005 | A1 |
| 20050281788 | De Bari | Dec 2005 | A1 |
| 20050281856 | McGlohorn et al. | Dec 2005 | A1 |
| 20050282275 | Katz | Dec 2005 | A1 |
| 20050283255 | Geremakis et al. | Dec 2005 | A1 |
| 20050288796 | Awad | Dec 2005 | A1 |
| 20060002900 | Binder | Jan 2006 | A1 |
| 20060018887 | Kadiyala | Jan 2006 | A1 |
| 20060030948 | Manrique | Feb 2006 | A1 |
| 20060041033 | Bisig et al. | Feb 2006 | A1 |
| 20060045872 | Miguel | Mar 2006 | A1 |
| 20060051327 | Johnson | Mar 2006 | A1 |
| 20060051865 | Higgins | Mar 2006 | A1 |
| 20060058881 | Trieu | Mar 2006 | A1 |
| 20060073124 | Garcia | Apr 2006 | A1 |
| 20060078993 | Phan | Apr 2006 | A1 |
| 20060083720 | Fraser | Apr 2006 | A1 |
| 20060084602 | Lynch | Apr 2006 | A1 |
| 20060121004 | Echeland | Jun 2006 | A1 |
| 20060136068 | de Brujin | Jun 2006 | A1 |
| 20060147424 | Sakuragawwa | Jul 2006 | A1 |
| 20060147430 | Sayre | Jul 2006 | A1 |
| 20060147433 | Hiles | Jul 2006 | A1 |
| 20060147545 | Scarborough | Jul 2006 | A1 |
| 20060153815 | Seyda | Jul 2006 | A1 |
| 20060153816 | Brown et al. | Jul 2006 | A1 |
| 20060153817 | Kihm | Jul 2006 | A1 |
| 20060153818 | Ohanaraj | Jul 2006 | A1 |
| 20060153928 | Kinoshita | Jul 2006 | A1 |
| 20060171930 | Seyda | Aug 2006 | A1 |
| 20060171932 | Hendricks | Aug 2006 | A1 |
| 20060198863 | De Paula | Sep 2006 | A1 |
| 20060204544 | Sunwoo et al. | Sep 2006 | A1 |
| 20060204556 | Daniels | Sep 2006 | A1 |
| 20060222634 | Clarke | Oct 2006 | A1 |
| 20060228339 | Wang | Oct 2006 | A1 |
| 20060228796 | Kolkin | Oct 2006 | A1 |
| 20060240555 | Ronfard | Oct 2006 | A1 |
| 20060263335 | France | Nov 2006 | A1 |
| 20070003593 | Wironen | Jan 2007 | A1 |
| 20070025973 | Fitzsimmons | Feb 2007 | A1 |
| 20070026518 | Healy | Feb 2007 | A1 |
| 20070027543 | Gimble | Feb 2007 | A1 |
| 20070036768 | Fraser | Feb 2007 | A1 |
| 20070048292 | Morita | Mar 2007 | A1 |
| 20070056597 | Fitzsimmons | Mar 2007 | A1 |
| 20070065938 | Gronthos | Mar 2007 | A1 |
| 20070071740 | Tseng | Mar 2007 | A1 |
| 20070071828 | Tseng | Mar 2007 | A1 |
| 20070077649 | Sammak | Apr 2007 | A1 |
| 20070082057 | Masinaei et al. | Apr 2007 | A1 |
| 20070082058 | Masinaei et al. | Apr 2007 | A1 |
| 20070083270 | Masinaei | Apr 2007 | A1 |
| 20070088437 | Betz et al. | Apr 2007 | A1 |
| 20070090101 | Yamazaki et al. | Apr 2007 | A1 |
| 20070092492 | Matsuda | Apr 2007 | A1 |
| 20070098756 | Behnam | May 2007 | A1 |
| 20070104692 | Quijano | May 2007 | A1 |
| 20070104693 | Quijano | May 2007 | A1 |
| 20070110732 | Johnson | May 2007 | A1 |
| 20070110820 | Behnam | May 2007 | A1 |
| 20070128171 | Tranquillo | Jun 2007 | A1 |
| 20070128173 | Verbruggen | Jun 2007 | A1 |
| 20070134210 | Heida | Jun 2007 | A1 |
| 20070134211 | Halvorsen | Jun 2007 | A1 |
| 20070148766 | Yoshimura | Jun 2007 | A1 |
| 20070154515 | Johnson | Jul 2007 | A1 |
| 20070154563 | Benham | Jul 2007 | A1 |
| 20070168038 | Trieu | Jul 2007 | A1 |
| 20070172812 | Ochi | Jul 2007 | A1 |
| 20070185585 | Bracy | Aug 2007 | A1 |
| 20070190034 | Paludan et al. | Aug 2007 | A1 |
| 20070190101 | McKay | Aug 2007 | A1 |
| 20070196421 | Hunter | Aug 2007 | A1 |
| 20070202592 | Kitagawa et al. | Aug 2007 | A1 |
| 20070207127 | Kato | Sep 2007 | A1 |
| 20070212336 | Fulkerson et al. | Sep 2007 | A1 |
| 20070212396 | Zheng | Sep 2007 | A1 |
| 20070212676 | Takakura | Sep 2007 | A1 |
| 20070213822 | Trieu | Sep 2007 | A1 |
| 20070213823 | Trieu | Sep 2007 | A1 |
| 20070213824 | Trieu | Sep 2007 | A1 |
| 20070218039 | Devi | Sep 2007 | A1 |
| 20070023272 | Boyce | Oct 2007 | A1 |
| 20070231297 | Smith | Oct 2007 | A1 |
| 20070231305 | Noll | Oct 2007 | A1 |
| 20070231401 | Tseng | Oct 2007 | A1 |
| 20070233272 | Boyce | Oct 2007 | A1 |
| 20070243130 | Chen et al. | Oct 2007 | A1 |
| 20070243131 | Chen et al. | Oct 2007 | A1 |
| 20070243172 | Ra | Oct 2007 | A1 |
| 20070248580 | Garcia | Oct 2007 | A1 |
| 20070248998 | Zhang | Oct 2007 | A1 |
| 20070249044 | Desai | Oct 2007 | A1 |
| 20070249045 | Gimble | Oct 2007 | A1 |
| 20070254041 | Drapeau et al. | Nov 2007 | A1 |
| 20070258956 | Higgins | Nov 2007 | A1 |
| 20070264239 | Huard | Nov 2007 | A1 |
| 20070264240 | Slavin | Nov 2007 | A1 |
| 20070269518 | Walline et al. | Nov 2007 | A1 |
| 20070275362 | Edinger | Nov 2007 | A1 |
| 20070276489 | Bindsell | Nov 2007 | A1 |
| 20070282456 | Geng | Dec 2007 | A1 |
| 20070292401 | Harmon | Dec 2007 | A1 |
| 20070292872 | Sylvester | Dec 2007 | A1 |
| 20070299508 | Morrison | Dec 2007 | A1 |
| 20080004713 | Nakamura | Jan 2008 | A1 |
| 20080014179 | Ferree | Jan 2008 | A1 |
| 20080015709 | Evans | Jan 2008 | A1 |
| 20080025957 | Lapidol | Jan 2008 | A1 |
| 20080026461 | Desphpande | Jan 2008 | A1 |
| 20080027546 | Semler | Jan 2008 | A1 |
| 20080030399 | Hunziker | Feb 2008 | A1 |
| 20080031858 | Chan | Feb 2008 | A1 |
| 20080033572 | D'Antonio | Feb 2008 | A1 |
| 20080038314 | Hunziker | Feb 2008 | A1 |
| 20080039940 | Hashimoto | Feb 2008 | A1 |
| 20080039955 | Hunziker | Feb 2008 | A1 |
| 20080046095 | Daniel | Feb 2008 | A1 |
| 20080050814 | Allickson | Feb 2008 | A1 |
| 20080057578 | Kuwabara | Mar 2008 | A1 |
| 20080058953 | Scarborough | Mar 2008 | A1 |
| 20080071385 | Binette | Mar 2008 | A1 |
| 20080075657 | Abrahams et al. | Mar 2008 | A1 |
| 20080075699 | Buhring | Mar 2008 | A1 |
| 20080077251 | Chen | Mar 2008 | A1 |
| 20080081369 | Adkisson | Apr 2008 | A1 |
| 20080089871 | Hunziker | Apr 2008 | A1 |
| 20080091270 | Miller | Apr 2008 | A1 |
| 20080095748 | Khariz | Apr 2008 | A1 |
| 20080108045 | Ghinelli | May 2008 | A1 |
| 20080112837 | Yoshizawa | May 2008 | A1 |
| 20080113007 | Kurihara | May 2008 | A1 |
| 20080131522 | Liu | Jun 2008 | A1 |
| 20080152624 | Paludan | Jun 2008 | A1 |
| 20080152629 | Edinger | Jun 2008 | A1 |
| 20080153157 | Yao | Jun 2008 | A1 |
| 20080154386 | Morris et al. | Jun 2008 | A1 |
| 20080160085 | Boland | Jul 2008 | A1 |
| 20080161410 | Kusters | Jul 2008 | A1 |
| 20080175824 | Heidaran | Jul 2008 | A1 |
| 20080175825 | Hampson | Jul 2008 | A1 |
| 20080181967 | Liu | Jul 2008 | A1 |
| 20080187518 | Ogle | Aug 2008 | A1 |
| 20080188945 | Boyce | Aug 2008 | A1 |
| 20080193554 | Dua | Aug 2008 | A1 |
| 20080199443 | Moos | Aug 2008 | A1 |
| 20080206208 | Casteilla | Aug 2008 | A1 |
| 20080206343 | Edinger | Aug 2008 | A1 |
| 20080213228 | Edinger | Sep 2008 | A1 |
| 20080213230 | Phillips | Sep 2008 | A1 |
| 20080213235 | Katz | Sep 2008 | A1 |
| 20080220569 | Previtali | Sep 2008 | A1 |
| 20080221527 | Bradley | Sep 2008 | A1 |
| 20080226595 | Edinger | Sep 2008 | A1 |
| 20080226612 | Treves | Sep 2008 | A1 |
| 20080226692 | Sato | Sep 2008 | A1 |
| 20080233088 | Guha | Sep 2008 | A1 |
| 20080233203 | Woodell-May | Sep 2008 | A1 |
| 20080248003 | Katz | Oct 2008 | A1 |
| 20080248005 | Phan | Oct 2008 | A1 |
| 20080248481 | Rapko | Oct 2008 | A1 |
| 20080254092 | McDevitt | Oct 2008 | A1 |
| 20080260703 | Riordan | Oct 2008 | A1 |
| 20080260794 | Lauritzen et al. | Oct 2008 | A1 |
| 20080269762 | Simon | Oct 2008 | A1 |
| 20080274185 | Mao | Nov 2008 | A1 |
| 20080286241 | Lee | Nov 2008 | A1 |
| 20080286267 | Sing | Nov 2008 | A1 |
| 20080286324 | Stolen | Nov 2008 | A1 |
| 20080288085 | Mao | Nov 2008 | A1 |
| 20080299087 | Tseng | Dec 2008 | A1 |
| 20080305145 | Shelby | Dec 2008 | A1 |
| 20080317718 | Youshimura | Dec 2008 | A1 |
| 20080318317 | Roche | Dec 2008 | A1 |
| 20090004161 | Palladino | Jan 2009 | A1 |
| 20090010899 | Palladino | Jan 2009 | A1 |
| 20090010982 | Abrahams et al. | Jan 2009 | A1 |
| 20090012629 | Yao | Jan 2009 | A1 |
| 20090017438 | Roy | Jan 2009 | A1 |
| 20090017439 | Shimko | Jan 2009 | A1 |
| 20090022698 | Ha | Jan 2009 | A1 |
| 20090024223 | Chen | Jan 2009 | A1 |
| 20090024224 | Chen | Jan 2009 | A1 |
| 20090024229 | Chen | Jan 2009 | A1 |
| 20090028834 | Siegel | Jan 2009 | A1 |
| 20090028919 | Dancu | Jan 2009 | A1 |
| 20090028954 | Bohner et al. | Jan 2009 | A1 |
| 20090035282 | Schierhotz | Feb 2009 | A1 |
| 20090041825 | Kotov | Feb 2009 | A1 |
| 20090043400 | Evans et al. | Feb 2009 | A1 |
| 20090053277 | Nagaya | Feb 2009 | A1 |
| 20090054983 | Wuisman | Feb 2009 | A1 |
| 20090060974 | Schmieding | Mar 2009 | A1 |
| 20090062870 | Milano | Mar 2009 | A1 |
| 20090068154 | Ueda | Mar 2009 | A1 |
| 20090074728 | Gronthos | Mar 2009 | A1 |
| 20090074753 | Lynch | Mar 2009 | A1 |
| 20090075381 | Clarke | Mar 2009 | A1 |
| 20090075863 | O'Driscoll | Mar 2009 | A1 |
| 20090082717 | Bellomo | Mar 2009 | A1 |
| 20090093056 | Iskovitz-Eldor | Apr 2009 | A1 |
| 20090104164 | Zhang | Apr 2009 | A1 |
| 20090130067 | Buscher | May 2009 | A1 |
| 20090130173 | Behnam et al. | May 2009 | A1 |
| 20090130756 | Klann | May 2009 | A1 |
| 20090136457 | Sing | May 2009 | A1 |
| 20090136471 | Heidaran | May 2009 | A1 |
| 20090136988 | Reschiglian | May 2009 | A1 |
| 20090142311 | Masuda | Jun 2009 | A1 |
| 20090142835 | Kobayashi | Jun 2009 | A1 |
| 20090143716 | Lowry | Jun 2009 | A1 |
| 20090143830 | Bourgeois | Jun 2009 | A1 |
| 20090149893 | Semler et al. | Jun 2009 | A1 |
| 20090155340 | Chu | Jun 2009 | A1 |
| 20090162445 | Masinaei | Jun 2009 | A1 |
| 20090163990 | Yang | Jun 2009 | A1 |
| 20090169642 | Fradette | Jul 2009 | A1 |
| 20090170059 | Klingerman | Jul 2009 | A1 |
| 20090175954 | Kinoshita | Jul 2009 | A1 |
| 20090181104 | Rigotti | Jul 2009 | A1 |
| 20090181456 | Hedrick | Jul 2009 | A1 |
| 20090185978 | Lundgren-Akerlund | Jul 2009 | A1 |
| 20090191160 | Hong | Jul 2009 | A1 |
| 20090196901 | Guilak | Aug 2009 | A1 |
| 20090202977 | Ott | Aug 2009 | A1 |
| 20090206313 | Beretta | Aug 2009 | A1 |
| 20090209020 | Park | Aug 2009 | A1 |
| 20090214649 | Gazit | Aug 2009 | A1 |
| 20090022086 | Lui | Sep 2009 | A1 |
| 20090022605 | Wei | Sep 2009 | A1 |
| 20090022704 | Troxel | Sep 2009 | A1 |
| 20090220605 | Wei et al. | Sep 2009 | A1 |
| 20090221075 | Dorian | Sep 2009 | A1 |
| 20090222086 | Lui | Sep 2009 | A1 |
| 20090228105 | Son | Sep 2009 | A1 |
| 20090232772 | Amano | Sep 2009 | A1 |
| 20090238801 | Woodbury | Sep 2009 | A1 |
| 20090239299 | Buss | Sep 2009 | A1 |
| 20090246182 | Castella | Oct 2009 | A1 |
| 20090252710 | Zhang | Oct 2009 | A1 |
| 20090252711 | Boquest | Oct 2009 | A1 |
| 20090258082 | Nikaido | Oct 2009 | A1 |
| 20090258337 | Yagi | Oct 2009 | A1 |
| 20090269315 | Fraser | Oct 2009 | A1 |
| 20090269388 | Sunwoo et al. | Oct 2009 | A1 |
| 20090274665 | Akabutu | Nov 2009 | A1 |
| 20090275011 | Eibl | Nov 2009 | A1 |
| 20090291112 | Truncale et al. | Nov 2009 | A1 |
| 20090292311 | Garcia | Nov 2009 | A1 |
| 20090297488 | Fraser | Dec 2009 | A1 |
| 20090304643 | Khurgei | Dec 2009 | A1 |
| 20090304644 | Hadrick | Dec 2009 | A1 |
| 20090304646 | Sakurada | Dec 2009 | A1 |
| 20090304654 | Lue | Dec 2009 | A1 |
| 20090311223 | Ichim | Dec 2009 | A1 |
| 20100003299 | Tseng | Jan 2010 | A1 |
| 20100008967 | Grande | Jan 2010 | A1 |
| 20100015104 | Fraser | Jan 2010 | A1 |
| 20100015204 | Hedrick | Jan 2010 | A1 |
| 20100015712 | Sakuragawa | Jan 2010 | A1 |
| 20100022005 | March | Jan 2010 | A1 |
| 20100003488 | Walline et al. | Feb 2010 | A1 |
| 20100028306 | Clarke | Feb 2010 | A1 |
| 20100028308 | Knipper | Feb 2010 | A1 |
| 20100028407 | Del | Feb 2010 | A1 |
| 20100036503 | Chen | Feb 2010 | A1 |
| 20100047213 | Zeitlin | Feb 2010 | A1 |
| 20100047214 | Abramson | Feb 2010 | A1 |
| 20100047351 | Zeitlin | Feb 2010 | A1 |
| 20100049322 | McKay | Feb 2010 | A1 |
| 20100055757 | Lin | Mar 2010 | A1 |
| 20100068180 | Marshall | Mar 2010 | A1 |
| 20100069975 | Auge | Mar 2010 | A1 |
| 20100080779 | Smith | Apr 2010 | A1 |
| 20100082113 | Gingras | Apr 2010 | A1 |
| 20100098669 | Fernandez | Apr 2010 | A1 |
| 20100098673 | D'Antonio | Apr 2010 | A1 |
| 20100098739 | Katz | Apr 2010 | A1 |
| 20100098743 | Nikaido | Apr 2010 | A1 |
| 20100104539 | Daniel | Apr 2010 | A1 |
| 20100104542 | Austen, Jr. | Apr 2010 | A1 |
| 20100105100 | Sakurada | Apr 2010 | A1 |
| 20100106233 | Grant | Apr 2010 | A1 |
| 20100111897 | Katz et al. | May 2010 | A1 |
| 20100111906 | Scarborough et al. | May 2010 | A1 |
| 20100112031 | Katz | May 2010 | A1 |
| 20100112084 | Wu | May 2010 | A1 |
| 20100112543 | Ngo | May 2010 | A1 |
| 20100112695 | Min | May 2010 | A1 |
| 20100112696 | Min | May 2010 | A1 |
| 20100114013 | Boyden | May 2010 | A1 |
| 20100119492 | Hans | May 2010 | A1 |
| 20100119496 | Wilkison | May 2010 | A1 |
| 20100120069 | Sakurada | May 2010 | A1 |
| 20100124563 | Coleman | May 2010 | A1 |
| 20100124569 | Abbot | May 2010 | A1 |
| 20100124776 | Shi | May 2010 | A1 |
| 20100129328 | Sing | May 2010 | A1 |
| 20100129330 | Wilkison | May 2010 | A1 |
| 20100050878 | Bellomo | Jun 2010 | A1 |
| 20100136114 | Mao | Jun 2010 | A1 |
| 20100136668 | Hedrick | Jun 2010 | A1 |
| 20100143312 | Hariri | Jun 2010 | A1 |
| 20100143477 | Siegel | Jun 2010 | A1 |
| 20100145473 | Yannas | Jun 2010 | A1 |
| 20100150878 | Bellomo | Jun 2010 | A1 |
| 20100151435 | Thatte | Jun 2010 | A1 |
| 20100151574 | Matsuyama | Jun 2010 | A1 |
| 20100158876 | Alessandri | Jun 2010 | A1 |
| 20100158975 | Naughton | Jun 2010 | A1 |
| 20100166716 | Serikov | Jul 2010 | A1 |
| 20100166824 | Naughton | Jul 2010 | A1 |
| 20100166879 | Shim | Jul 2010 | A1 |
| 20100168022 | Centeno | Jul 2010 | A1 |
| 20100173352 | Blanc-Brude | Jul 2010 | A1 |
| 20100173411 | Katz | Jul 2010 | A1 |
| 20100178274 | Sekiya | Jul 2010 | A1 |
| 20100178861 | Lee | Jul 2010 | A1 |
| 20100183568 | Matuyama | Jul 2010 | A1 |
| 20100183571 | Paludan | Jul 2010 | A1 |
| 20100196333 | Gaskins | Aug 2010 | A1 |
| 20100196439 | Beck | Aug 2010 | A1 |
| 20100196480 | Hiles | Aug 2010 | A1 |
| 20100209387 | Wasielewski | Aug 2010 | A1 |
| 20100209408 | Stepen | Aug 2010 | A1 |
| 20100209470 | Mohan | Aug 2010 | A1 |
| 20100215714 | Messina | Aug 2010 | A1 |
| 20100215717 | Soker | Aug 2010 | A1 |
| 20100027399 | Funaki | Sep 2010 | A1 |
| 20100221231 | Smith | Sep 2010 | A1 |
| 20100221268 | Parolini | Sep 2010 | A1 |
| 20100233131 | Kang | Sep 2010 | A1 |
| 20100233139 | Hedrick | Sep 2010 | A1 |
| 20100239539 | Sing | Sep 2010 | A1 |
| 20100239540 | Brinchmann | Sep 2010 | A1 |
| 20100239542 | Young | Sep 2010 | A1 |
| 20100239543 | Young | Sep 2010 | A1 |
| 20100249758 | Sengun | Sep 2010 | A1 |
| 20100254954 | Sakuragawa | Oct 2010 | A1 |
| 20100255115 | Mohan | Oct 2010 | A1 |
| 20100256774 | Wang | Oct 2010 | A1 |
| 20100260843 | Messina | Oct 2010 | A1 |
| 20100261276 | Park | Oct 2010 | A1 |
| 20100266553 | Ra | Oct 2010 | A1 |
| 20100267107 | Zuba-Surma | Oct 2010 | A1 |
| 20100272694 | Yang | Oct 2010 | A1 |
| 20100272803 | Mistry | Oct 2010 | A1 |
| 20100278783 | Rouy | Nov 2010 | A1 |
| 20100279405 | Peterson | Nov 2010 | A1 |
| 20100285521 | Vossman | Nov 2010 | A1 |
| 20100285580 | Evans | Nov 2010 | A1 |
| 20100285582 | Choung | Nov 2010 | A1 |
| 20100285588 | Stubbers | Nov 2010 | A1 |
| 20100291042 | Crawford | Nov 2010 | A1 |
| 20100291219 | Karp | Nov 2010 | A1 |
| 20100291679 | Edinger | Nov 2010 | A1 |
| 20100292791 | Lu | Nov 2010 | A1 |
| 20100297082 | Guelcher | Nov 2010 | A1 |
| 20100297089 | Oh | Nov 2010 | A1 |
| 20100297689 | Edinger | Nov 2010 | A1 |
| 20100030774 | Hedrick | Dec 2010 | A1 |
| 20100303766 | Miyaji | Dec 2010 | A1 |
| 20100303773 | Yang | Dec 2010 | A1 |
| 20100303774 | Hedrick | Dec 2010 | A1 |
| 20100304477 | Buscher | Dec 2010 | A1 |
| 20100305696 | Mao | Dec 2010 | A1 |
| 20100310527 | Alt | Dec 2010 | A1 |
| 20100312355 | Yahav | Dec 2010 | A1 |
| 20100330047 | Valorani | Dec 2010 | A1 |
| 20100330182 | Young | Dec 2010 | A1 |
| 20100330672 | Sakuragawa | Dec 2010 | A1 |
| 20100330673 | Fraser | Dec 2010 | A1 |
| 20110002904 | Johnson | Jan 2011 | A1 |
| 20110003387 | Abbot | Jan 2011 | A1 |
| 20110003388 | Fraser | Jan 2011 | A1 |
| 20110008300 | Wouters | Jan 2011 | A1 |
| 20110008397 | Cohen | Jan 2011 | A1 |
| 20110008763 | Lee | Jan 2011 | A1 |
| 20110009963 | Binnette | Jan 2011 | A1 |
| 20110014701 | Ghosh | Jan 2011 | A1 |
| 20110020196 | Grippi | Jan 2011 | A1 |
| 20110020293 | Woda | Jan 2011 | A1 |
| 20110027871 | Gaskins | Feb 2011 | A1 |
| 20110027879 | Katz | Feb 2011 | A1 |
| 20110028903 | Schmieding | Feb 2011 | A1 |
| 20110038903 | Singh | Feb 2011 | A1 |
| 20110039332 | Sakurada | Feb 2011 | A1 |
| 20110040388 | Alini | Feb 2011 | A1 |
| 20110045044 | Masinaei | Feb 2011 | A1 |
| 20110045084 | Walline et al. | Feb 2011 | A1 |
| 20110045588 | Kawase | Feb 2011 | A1 |
| 20110045949 | Kunihara | Feb 2011 | A1 |
| 20110046628 | Jamali | Feb 2011 | A1 |
| 20110046758 | Soo et al. | Feb 2011 | A1 |
| 20110059178 | Semler et al. | Mar 2011 | A1 |
| 20110064701 | Young | Mar 2011 | A1 |
| 20110064705 | Lanza | Mar 2011 | A1 |
| 20110064810 | Ghanawi | Mar 2011 | A1 |
| 20110065083 | Shimko | Mar 2011 | A1 |
| 20110070205 | Crawford | Mar 2011 | A1 |
| 20110070312 | Wei et al. | Mar 2011 | A1 |
| 20110070647 | Oezawa | Mar 2011 | A1 |
| 20110077679 | Moran | Mar 2011 | A1 |
| 20110081326 | Hantash | Apr 2011 | A1 |
| 20110086008 | Hoemann | Apr 2011 | A1 |
| 20110086068 | Gourdie | Apr 2011 | A1 |
| 20110086426 | Freund | Apr 2011 | A1 |
| 20110087338 | Seimionow | Apr 2011 | A1 |
| 20110091517 | Ginette | Apr 2011 | A1 |
| 20110097381 | Binette | Apr 2011 | A1 |
| 20110098826 | Mauck | Apr 2011 | A1 |
| 20110104133 | Tseng | May 2011 | A1 |
| 20110104735 | Bueher | May 2011 | A1 |
| 20110108644 | Morris et al. | May 2011 | A1 |
| 20110110896 | Kleinsek | May 2011 | A1 |
| 20110110898 | Kleinsek | May 2011 | A1 |
| 20110111497 | Tamai | May 2011 | A1 |
| 20110111499 | Torihashi | May 2011 | A1 |
| 20110117167 | Sanford | May 2011 | A1 |
| 20110117171 | Melican | May 2011 | A1 |
| 20110117650 | Riodan | May 2011 | A1 |
| 20110124105 | Hampson | May 2011 | A1 |
| 20110129447 | Meretzki | Jun 2011 | A1 |
| 20110143331 | Roy | Jun 2011 | A1 |
| 20110143429 | Chun | Jun 2011 | A1 |
| 20110150845 | Parekkadan | Jun 2011 | A1 |
| 20110150846 | Van | Jun 2011 | A1 |
| 20110151005 | Ylikomi | Jun 2011 | A1 |
| 20110151011 | Flynn | Jun 2011 | A1 |
| 20110158959 | Mcintosh | Jun 2011 | A1 |
| 20110158966 | Seilgman | Jun 2011 | A1 |
| 20110158968 | Fraser | Jun 2011 | A1 |
| 20110158995 | Mcintosh | Jun 2011 | A1 |
| 20110171726 | Kang | Jul 2011 | A1 |
| 20110172777 | Sybert et al. | Jul 2011 | A1 |
| 20110177132 | Allon | Jul 2011 | A1 |
| 20110177134 | Harmon | Jul 2011 | A1 |
| 20110177593 | Funaki | Jul 2011 | A1 |
| 20110182962 | McKay | Jul 2011 | A1 |
| 20110182963 | McKay | Jul 2011 | A1 |
| 20110183001 | Rosson | Jul 2011 | A1 |
| 20110184381 | Shintani | Jul 2011 | A1 |
| 20110189140 | Christman | Aug 2011 | A1 |
| 20110189254 | Liu | Aug 2011 | A1 |
| 20110189696 | Gronthos | Aug 2011 | A1 |
| 20110195052 | Benham et al. | Aug 2011 | A1 |
| 20110262554 | Masinaei et al. | Oct 2011 | A1 |
| 20110274668 | Scarborough et al. | Nov 2011 | A1 |
| 20120009230 | Orapeu | Jan 2012 | A1 |
| 20120046758 | Evans | Feb 2012 | A1 |
| 20120053692 | Voor | Mar 2012 | A1 |
| 20120088721 | Shiedlin et al. | Apr 2012 | A1 |
| 20120093895 | Song | Apr 2012 | A1 |
| 20120100225 | McKay | Apr 2012 | A1 |
| 20120116515 | Semler | May 2012 | A1 |
| 20120121660 | Akella | May 2012 | A1 |
| 20120212913 | Walline et al. | May 2012 | A1 |
| 20120143334 | Boyce | Jun 2012 | A1 |
| 20120156265 | Binette | Jun 2012 | A1 |
| 20120189704 | Ben-Shalom et al. | Jul 2012 | A1 |
| 20120195952 | King | Aug 2012 | A1 |
| 20120205274 | Sunwoo et al. | Aug 2012 | A1 |
| 20120213859 | Shelby | Aug 2012 | A1 |
| 20120251609 | Huang | Oct 2012 | A1 |
| 20120258178 | Behnam et al. | Oct 2012 | A1 |
| 20120259425 | Brahm | Oct 2012 | A1 |
| 20120269892 | Mussand | Oct 2012 | A1 |
| 20120294896 | Roper | Nov 2012 | A1 |
| 20120294898 | Hubbard et al. | Nov 2012 | A1 |
| 20120330423 | Lin | Dec 2012 | A1 |
| 20130013071 | Betz et al. | Jan 2013 | A1 |
| 20130073041 | Seifert | Mar 2013 | A1 |
| 20130115255 | Bosley | May 2013 | A1 |
| 20130136777 | Behnam | May 2013 | A1 |
| 20130149356 | Mills | Jun 2013 | A1 |
| 20130158676 | Hayzlett | Jun 2013 | A1 |
| 20130189338 | Drapeau | Jul 2013 | A1 |
| 20130190891 | Drapeau et al. | Jul 2013 | A1 |
| 20130190893 | Roock | Jul 2013 | A1 |
| 20130195805 | Wei et al. | Aug 2013 | A1 |
| 20130261634 | McKay | Oct 2013 | A1 |
| 20130273121 | Mizuno | Oct 2013 | A1 |
| 20130287741 | Stillwell | Oct 2013 | A1 |
| 20130287753 | Centeno | Oct 2013 | A1 |
| 20130295081 | Guelcher et al. | Nov 2013 | A1 |
| 20130297038 | McKay | Nov 2013 | A1 |
| 20130316012 | Gaskins et al. | Nov 2013 | A1 |
| 20130331898 | Nyemsceck | Dec 2013 | A1 |
| 20140010891 | Morris et al. | Jan 2014 | A1 |
| 20140031937 | McKay | Jan 2014 | A1 |
| 20140065238 | Wolfinbarger | Mar 2014 | A1 |
| 20140121771 | Chitre | May 2014 | A1 |
| 20140195005 | McKay | Jul 2014 | A1 |
| 20140205674 | Wei | Jul 2014 | A1 |
| 20140207235 | Drapeau | Jul 2014 | A1 |
| 20140208980 | Song et al. | Jul 2014 | A1 |
| 20140212471 | Drapeau et al. | Jul 2014 | A1 |
| 20140212499 | Cooper et al. | Jul 2014 | A1 |
| 20140220142 | Song et al. | Aug 2014 | A1 |
| 20140242044 | Evans et al. | Aug 2014 | A1 |
| 20140261855 | Shimko et al. | Sep 2014 | A1 |
| 20140277569 | Lange | Sep 2014 | A1 |
| 20140277570 | Behnam et al. | Sep 2014 | A1 |
| 20140287017 | Altschuler | Sep 2014 | A1 |
| 20140296623 | Owens et al. | Oct 2014 | A1 |
| 20140302112 | Behnam et al. | Oct 2014 | A1 |
| 20140314821 | Scifert et al. | Oct 2014 | A1 |
| 20140314822 | Carter et al. | Oct 2014 | A1 |
| 20140341964 | McKay et al. | Nov 2014 | A1 |
| 20150010642 | Anderson et al. | Jan 2015 | A1 |
| 20150030684 | Pomrink et al. | Jan 2015 | A1 |
| 20150037386 | Shimp et al. | Feb 2015 | A1 |
| 20150110747 | Bhat et al. | Apr 2015 | A1 |
| 20150110748 | Shat et al. | Apr 2015 | A1 |
| 20150140096 | Malinin | May 2015 | A1 |
| 20150224227 | Bhat et al. | Aug 2015 | A1 |
| 20150251361 | Meyer et al. | Sep 2015 | A1 |
| 20150258243 | Malinin | Sep 2015 | A1 |
| 20150283168 | Ben-Shalom et al. | Oct 2015 | A1 |
| 20150283182 | Guelcher et al. | Oct 2015 | A1 |
| 20150283296 | Cao et al. | Oct 2015 | A1 |
| 20150297793 | McKay | Oct 2015 | A1 |
| 20160331554 | Manrique et al. | Jan 2016 | A1 |
| 20160038639 | Carter et al. | Feb 2016 | A1 |
| 20160081803 | McKay | Mar 2016 | A1 |
| 20160082155 | Uveges et al. | Mar 2016 | A1 |
| 20160115451 | Wolfinbarger et al. | Apr 2016 | A1 |
| 20160135954 | Schlachter | May 2016 | A1 |
| 20160136329 | Schlachter | May 2016 | A1 |
| 20160144075 | Behnam | May 2016 | A1 |
| 20160158408 | Pomrink et al. | Jun 2016 | A1 |
| 20160166303 | Schlacter | Jun 2016 | A1 |
| 20160166729 | Mossaad | Jun 2016 | A1 |
| 20160175480 | Altschuler et al. | Jun 2016 | A1 |
| 20160213811 | Chen et al. | Jul 2016 | A1 |
| 20160256607 | Francis et al. | Sep 2016 | A1 |
| 20160302931 | Forsell | Oct 2016 | A1 |
| 20160310636 | Scifert et al. | Oct 2016 | A1 |
| 20160361171 | Wang et al. | Dec 2016 | A1 |
| 20170000624 | Schallenberger et al. | Jan 2017 | A1 |
| 20170106119 | Skinner et al. | Apr 2017 | A1 |
| 20170119927 | Cooper et al. | May 2017 | A1 |
| 20170119929 | Bhat et al. | May 2017 | A1 |
| 20170119933 | McKay | May 2017 | A1 |
| 20170128624 | Muir | May 2017 | A1 |
| 20170136149 | Wei et al. | May 2017 | A1 |
| 20170165323 | Soo et al. | Jun 2017 | A1 |
| 20170203006 | Carter et al. | Jul 2017 | A1 |
| 20170203007 | Ringeisen et al. | Jul 2017 | A1 |
| 20170216491 | Schlachter et al. | Aug 2017 | A1 |
| 20170266348 | Gaskins et al. | Sep 2017 | A1 |
| 20170296357 | McKay et al. | Oct 2017 | A1 |
| 20170296581 | Behnam et al. | Oct 2017 | A1 |
| 20170312079 | Schlacter et al. | Nov 2017 | A1 |
| 20170319626 | Wei | Nov 2017 | A1 |
| 20170326162 | DiMauro | Nov 2017 | A1 |
| 20170326180 | DiMauro | Nov 2017 | A1 |
| 20170333485 | Marchosky | Nov 2017 | A1 |
| 20180000595 | Carter et al. | Jan 2018 | A1 |
| 20180021382 | Wei et al. | Jan 2018 | A1 |
| 20180028317 | Schlachter | Jan 2018 | A1 |
| 20180093014 | McKay | Apr 2018 | A1 |
| 20180104381 | Southard et al. | Apr 2018 | A1 |
| 20180133363 | Chen et al. | May 2018 | A1 |
| 20180177916 | Masinei et al. | Jun 2018 | A1 |
| 20180185548 | McKay | Jul 2018 | A1 |
| 20180193077 | Schlachter et al. | Jul 2018 | A1 |
| 20190091942 | Meyer et al. | Mar 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2177017 | Jun 1995 | CA |
| 250737 | Jun 2004 | CA |
| 25415061 | Nov 2010 | CA |
| 2986702 | Nov 2016 | CA |
| 0333328 | Sep 1989 | EP |
| 0518389 | Dec 1992 | EP |
| 0669138 | Aug 1995 | EP |
| 1127581 | Aug 2001 | EP |
| 1263365 | Dec 2002 | EP |
| 1283693 | Feb 2003 | EP |
| 1477176 | Nov 2004 | EP |
| 1505943 | Feb 2005 | EP |
| 1549358 | Jul 2005 | EP |
| 1847277 | Oct 2007 | EP |
| 2032071 | Mar 2009 | EP |
| 2129406 | Sep 2009 | EP |
| 3297694 | Mar 2018 | EP |
| 2004210713 | Jul 2004 | JP |
| 2006230749 | Sep 2006 | JP |
| 2007054015 | Mar 2007 | JP |
| 20040020413 | Mar 2004 | KR |
| 1989004646 | Jun 1989 | WO |
| 1989007425 | Aug 1989 | WO |
| 199515776 | Jun 1995 | WO |
| 1998037903 | Sep 1998 | WO |
| 1999039757 | Feb 1999 | WO |
| 2000045871 | Aug 2000 | WO |
| 2000073421 | Dec 2000 | WO |
| 2001023532 | Apr 2001 | WO |
| 2002005750 | Jan 2002 | WO |
| 2002002156 | Jan 2002 | WO |
| 2002005750 | Jan 2002 | WO |
| 2002005750 | Feb 2002 | WO |
| 2002028322 | Apr 2002 | WO |
| 2002032348 | Apr 2002 | WO |
| 2002036049 | Aug 2002 | WO |
| 2002068010 | Sep 2002 | WO |
| 2003077794 | Sep 2003 | WO |
| 2004000164 | Dec 2003 | WO |
| 2003099236 | Dec 2003 | WO |
| 20030099236 | Dec 2003 | WO |
| 2004016196 | Feb 2004 | WO |
| 2004016297 | Feb 2004 | WO |
| 20040016297 | Feb 2004 | WO |
| 2004033635 | Apr 2004 | WO |
| 2004026244 | Apr 2004 | WO |
| 2004045372 | Jun 2004 | WO |
| 2004045372 | Jun 2004 | WO |
| 20040045372 | Jun 2004 | WO |
| 2004071543 | Aug 2004 | WO |
| 2004078225 | Sep 2004 | WO |
| 2004112854 | Dec 2004 | WO |
| 2005009498 | Feb 2005 | WO |
| 2005032435 | Apr 2005 | WO |
| 2005051446 | Jun 2005 | WO |
| 2005072656 | Aug 2005 | WO |
| 2006076712 | Jul 2006 | WO |
| 2006089023 | Aug 2006 | WO |
| 2006094247 | Sep 2006 | WO |
| 2007090180 | Feb 2007 | WO |
| 2007037572 | Apr 2007 | WO |
| 2007038686 | Apr 2007 | WO |
| 2007124198 | Nov 2007 | WO |
| 2007133722 | Nov 2007 | WO |
| 20070133722 | Nov 2007 | WO |
| 2008003042 | Jan 2008 | WO |
| 2008026858 | Mar 2008 | WO |
| 2008072230 | Jun 2008 | WO |
| 2008073628 | Jun 2008 | WO |
| 2009036279 | Mar 2009 | WO |
| 2009038676 | Mar 2009 | WO |
| 2009082554 | Jul 2009 | WO |
| 2009102452 | Aug 2009 | WO |
| 2009102792 | Aug 2009 | WO |
| 2010016942 | Feb 2010 | WO |
| 2010146577 | Dec 2010 | WO |
| 2011005200 | Jan 2011 | WO |
| 2009036279 | May 2012 | WO |
| 2012058042 | May 2012 | WO |
| 2012060964 | May 2012 | WO |
| 2012060991 | May 2012 | WO |
| 2012061024 | May 2012 | WO |
| 2012135205 | Oct 2012 | WO |
| 20120135205 | Oct 2012 | WO |
| 2013047937 | Apr 2013 | WO |
| 2013109663 | Jul 2013 | WO |
| 2013188336 | Dec 2013 | WO |
| 2014145854 | Sep 2014 | WO |
| 2014151091 | Sep 2014 | WO |
| 2015054547 | Sep 2014 | WO |
| 2015054547 | Apr 2015 | WO |
| 2015120221 | Aug 2015 | WO |
| 2016048657 | Mar 2016 | WO |
| 2016123583 | Aug 2016 | WO |
| 2016187413 | Nov 2016 | WO |
| 2017218545 | Feb 2017 | WO |
| 2017070036 | Apr 2017 | WO |
| 2017074894 | May 2017 | WO |
| 2017132038 | Aug 2017 | WO |
| 2017189721 | Nov 2017 | WO |
| 2017196595 | Nov 2017 | WO |
| Entry |
|---|
| Office Action dated Feb. 1, 2021 for corresponding Canadian Patent Application No. 2986702. |
| Benjamin, “The Fascia of the limbs and back—a review”, Journal of Anatomy, vol. 214, (2009), pp. 1-18. |
| Final Office Action for U.S. Appl. No. 13/108,856, dated May 14, 2013. |
| Adipose Tissue, http://users.rcn.com/jkimball.ma.ultranet!BiologyPages/A/AdiposeTissue.html, dated Dec. 1, 2009, printedApr. 15, 2011, 1 page. |
| Alsalameh et al., “Identification of Mesenchymal Progenitor Cells in Normal and Osteoarthritic Human Articular cartilage”, Arthritis & Rheumatism, vol. 50, No. 5, May 2004, pp. 1522-1532. |
| Alvarez-Buylla et al., “For the Long Run: Maintaining Germinal Niches in the Adult Brain”, Neuron, vol. 41, Mar. 4, 2004 pp. 683-686. |
| Amir et al., “Harvesting Large Fascia Lala Sheaths: A Rational Approach”, Skull Base Surgery, vol. 10, No. 1, (2000), pp. 29-34. |
| Anderson et al., “The performance of human mesenchymal stem cells encapsulated in cell-degradable polymer-peptide hydrogels”, Biomaterials, vol. 32, (2011 }, pp. 3564-3574. |
| Antuna-Puente et al., “Adipokines: The missing link between insulin resistance and obesity”, Diabetes & Metabolism, vol. 34, (2008), pp. 2-11. |
| Bacterin International, Inc.: OsteoSponge®, dated Mar. 2006, from http://odev.com/health_professional/pdfs/spine/Osteosponge%20Brochure.pdf. 5 pages. |
| Badylak et al., “The extracellular matrix as a biologic scaffold material”, Biomaterials, vol. 28, (2007), pp. 3587-3593. |
| Bakopoulou et al., “Comparative Analysis of in vitro osteo/odontogenic differentiation potential of human dental pulp stern cells (DPSCs) and stem cells from the apical papilla (SCAP)”, Archives of Oral Biology, vol. 56, Jan. 10, 2011, pp. 709-721. |
| Bakopoulou et al., “Effects of HEMA and TEDGMA on the in vitro odontogenic differentiation potential of human pulp stern/progenitor cells derived from decidous teeth”, Dental Materials, vol. 27, Apr. 11, 2011, pp. 608-617. |
| Barker et al., “Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells”, Gastroenterology, vol. 138, No. 5, May 2010, pp. 1681-1696. |
| Becher et al., “Regeneration of the vascular compartment”, Herz, vol. 35, (2010), pp. 342-351. |
| Bi et al., “Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche”, Nature Medicine, vol. 13, No. 10, Oct. 2007, pp. 1219-1227. |
| Bieliauskas et al.; “Isoform-selective histone deacetylas inhibitors”. Chemical Society Reviews. vol. 37, (2008), pp. 1402-1412. |
| Bigham et al., “Xengogenic Demineralized bone matrix and fresh autogenous cortical bone effects on experimental bone healing: radiological, histopathological and biomechanical evaluation”, Journal of Orthopaed Traumatol, vol. 9, ( 2008), pp. 73-80. |
| Blanpain et al., “Epidermal homeostasis: a balancing act of stem cells in the skin”, Nat. Rev. Mol. Cell Bioi., vol. 10, No. 3, Mar. 2009, pp. 207-217. |
| Blanpain, “Skin regeneration and repair”, Nature, vol. 464, Apr. 11, 2010, pp. 686-687. |
| Boonen et al., “The Muscle Stem Cell Niche: Regulation of Satellite Cells During Regeneration”, Tissue Engineering: Part B, vol. 14, No. 4, (2008) pp. 419-431. |
| Brachium to Hand Musculature, http://www.ptcentral.com/muscles/musclearms.html, printed Apr. 15, 2011, 12 pages. |
| Bradner et al., “Chemical phylogenetics of histone deacetylases”, Nature Chemical Biology, vol. 6, Mar. 2010, pp. 238-240. |
| Breitling et al., “Robust signaling networks of the adipose secretome”, Trends in Endocrinology and Metabolism, vol. 20, No. 1, (2008), pp. 1-7. |
| Brochhausen et al., “Signalling molecules and growth factors for tissue engineering of cartilage—what can we learn frorr the growth plate?”, Journal of Tissue Engineering and Regenerative Medicine, vol. 3, (2009), pp. 416-429. |
| Brown et al., “Basic Science Review on Adipose Tissue for Clinicians”, Plastic and Reconstructive Surgery, vol. 126, No. 6, Dec. 2010, pp. 1936-1946. |
| Brown et al., “Comparison of Three Methods for the Derivation of a Biologic Scaffold Composed of Adipose Tissue Extracellular Matrix”, Tissue Engineering: Part C, vol. 17, No. 4 (2011), pp. 411-421. |
| Butler et al., “Dentin Extracellular Matrix (ECM) Proteins: Comparison to Bone ECM and Contribution to Dynamics of Dentinogenesis”, Connective Tissue Research, vol. 44 (Suppl. 1), (2003), pp. 171-178. |
| Chapman, “Toward Lung Regeneration”, The New England Journal of Medicine, vol. 364, No. 19, May 12, 2011, pp. 1867-1868. |
| Chen, “Extracellular Matrix Provides an Optimal Niche for the Maintenance and Propagation of Mesenchymal Stem Cells”, Birth Defects Research {Part C), vol. 90, {2010), pp. 45-54. |
| Cheng, et al., “Chondrogenic Differentiation of Adipose-Derived Adult Stem Cells by a Porous Scaffold Derived from Native Articular Cartilage Extracellular Matrix”, Tissue Engineering: Part A, vol. 15, No. 2, {2009), pp. 231-241. |
| Cheng, et al., “Comparison of Potentials Between Stem Cells Isolated from Human Anterior Cruciate Ligament and Bone Marrow for Ligament Tissue Engineering”, Tissue Engineering: Part A, vol. 16, No. 7, {2010), pp. 2237-2253. |
| Choi et al., “Decellularized extracellular matrix derived from human adipose tissue as a potential scaffold for allograft issue engineering”, J Biomed Mater Res A., Mar. 29, 2011, 1 page http://www.ncbi.nlm.hih.gov/pubmed printed Apr. 5, 2011 {abstract only. |
| Choi et al., “Fabrication of Porous Extracellular Matrix Scaffolds from Human Adipose Tissue”, Tissue Engineering: Part C, vol. 16, No. 3, {2010), pp. 387-396. |
| Chun et al., “Analysis of the Soluble Human Tooth Proteome and Its Ability to Induce Dentin/Tooth Regeneration”, issue Engineering: Part A, vol. 17, Nos. 1 & 2, {2011 }, pp. 181-191. |
| Cinti, “The Adipose Organ”, Prostaglandins Leukotrienes Essential Fatty Acids, vol. 73, No. 1, Jul. 2005, pp. 9-15. |
| Cosgrove et al., “A home away from home: Challenges and opportunities in engineering in vitro muscle satellite cell niches”, Differentiation, vol. 78, {2009), pp. 184-194. |
| Cowin, ed., “Bone Mechanics”, CRC Press, Inc., 1989, pp. 1-13. |
| Davisson et al., “Novel Allograft Sponge Supports Fill of Osteochondral Defects in Caprine Model,” 55th Annual Meeting of the Orthopaedic Research Society (Feb. 2009), Paper No. 57, 1 page. |
| Diaz-Prado et al., “Isolation and Characterization of Mesenchymal Stem Cells from Human Amniotic Membrane”, Tissue Engineering: Part C, vol. 17, No. 1, (2011 ), pp. 49-59. |
| DiBella et al., “Injection of Demineralized Bone Matrix with Bone Marrow Concentrate Improves Healing in Unicameral Bone Cyst,” Clinical Orthopaedics and Related Research, Symposium: Highlights of the ISOLS/MSTS, 2009 Meeting, 2009), 9 pages. |
| Discher et al., “Growth factors, matrices, and forces combine and control stem cells”, Science, vol. 324, No. 5935, Jun. 26, 2009, pp. 1673-1677. |
| Fascia, Wikipedia, http://en.wikipedia.org/wiki/Fascia, printed May 16, 2011,3 pages. |
| Feng et al., “Extracellular Matrix in Disc Degeneration”, The Journal of Bone & Joint Surgery, vol. 88, (2006), pp. 25-2S. |
| Fernandez-Tresguerres Hernandez-Gil, et al., “Physiological bases of bone regeneration I. Histology and physiology o bone tissue”, Med. Oral Patel Oral Cir. Bucal, vol. 11, (2006), pp. E47-E51. |
| Final Office Action for U.S. Appl. No. 13/690,542, dated Jul. 2, 2015. |
| Final Office Action for U.S. Appl. No. 13/828,525, dated Jul. 1, 2016. |
| Final Office Action for U.S. Appl. No. 13/828,525, dated Jul. 24, 2015. |
| Final Office Action for U.S. Appl. No. 13/948,798, dated Mar. 14, 2014. |
| Final Office Action for U.S. Appl. No. 13/828,525, dated May 12, 2017. |
| Final Office Action for U.S. Appl. No. 15/159,406, dated May 9, 2018. |
| Risau et al., “Vasculogenesis”, Annual Review of Cell and Developmental Biology, vol. 11, {1995), pp. 73-91. |
| Sandberg, “Matrix in Cartilage and Bone Development: Current Views on the Function and Regulation of Major Organic Components”, Annals of Medicine, vol. 23, {1991), pp. 207-217. |
| Sandjeu et al.,“Desmosealin and other Components of the Epidermal Extracellular Matrix”, Journal of Physiology and Pharmacology, vol. 60, Suppl. 4, {2009), pp. 23-30. |
| Schwam et al., Human Amniotic Membrane Transplantation for the Treatment of Ocular Surface Disease, DCMS Northeast Florida Medicine Journal, http://www.dmcsonline.org/jax-medicine/2002joumals/augsept2002/amniotic.htm, Aug.-Sep. 2002 (printed Aug. 30, 2010), 6 pages. |
| Shamji et al., “Proinflammatory Cytokine Expression Profile in Degenerated and Hemiated Human Intervertebral Disc Tissues”, Arthritis & Rheumatism, vol. 62, No. 7, Jul. 2010, pp. 1974-1982. |
| Sheikh et al., “Cell-Cell Connection to Cardiac Disease”, TCM, vol. 19, No. 6, {2009), pp. 182-190. |
| Shoulders et al, “Collagen Structure and Stability”, Annu Rev Biochem., vol. 78, {2009), pp. 927-958. |
| Smith et al., “Degeneration and regeneration of the intervertebral disc: lessons from development”, Dis. Model Mech., vol. 4, No. 1, Jan. 2011, pp. 31-41. |
| Som et al., “Fascia and Spaces of the Neck”, Head and Neck Imaging, 4th Ed., Chapter 34, Mosby, Inc., {2003), pp. 1805-1827. |
| Somerman et al., “Human Dentin Matrix Induces Cartilage Formation in vitro Mesenchymal Cells Derived from embryonic Muscle”, J Den Res, vol. 66, No. 10, Oct. 1987, pp. 1551-1558. |
| Steiner et al., “Mesenchymal Stem Cell Characteristics of Human Anterior Cruciate Ligament Outgrowth cells”, Tissue Eng., Part A, vol. 17, No. 9 and 10, pp. 1375-1388, 2011. |
| Stem Cell Basics, U.S. Department of Health and Human Services, National Institutes of Health, http://stemcells.hih/gov/info/basics/, last updated: Apr. 28, 2009, 26 pages. |
| The Hosford Muscle Tables: Skeletal Muscles of the Human Body, http://www.ptcentral.com/muscles/, printed Apr. 15, 2011, 3 pages. |
| Thesleff et al., “Cell-matrix interactions in tooth development”, Int. J. Dev. Bioi., vol. 33, (1989), pp. 91-97. |
| Tilki et al., “Emerging biology of vascular wall progenitor cells in health and disease”, Trends in Molecular Medicine, vol. 15, No. 11, (2009), pp. 501-509. |
| Trombi et al., “Human Autologous Plasma-Derived Clot as a Biological Scaffold for Mesenchymal Stem Cells in Treatment of Orthopedic Healing,” Journal of Orthopaedic Research (Feb. 2009), pp. 176-183. |
| Trujillo et al., “Adipose Tissue-Derived Factors: Impact on Health and Disease”, Endocrine Reviews, vol. 27, No. 7, 2006), pp. 762-778. |
| U.S. Appl. No. 09/517,981, filed Mar. 3, 2000. |
| U.S. Appl. No. 15/159,406, filed May 19, 2016. |
| U.S. Appl. No. 13/828,525, filed Mar. 14, 2013. |
| U.S. Appl. No. 14/537,253, filed Nov. 10, 2014. |
| U.S. Appl. No. 14/933,176, filed Nov. 5, 2015. |
| U.S. Appl. No. 14/942,292, filed Nov. 16, 2015. |
| U.S. Appl. No. 15/288,539, filed Oct. 7, 2016. |
| U.S. Appl. No. 60/219,198, filed Jul. 19, 2000. |
| U.S. Appl. No. 60/288,212, filed May 2, 2001. |
| U.S. Appl. No. 60/970,721, filed Sep. 7, 2007. |
| U.S. Appl. No. 61/814,192, filed Apr. 19, 2013. |
| U.S. Appl. No. 61/864,499, filed Aug. 9, 2013. |
| U.S. Appl. No. 61/952,128, filed Mar. 12, 2014. |
| U.S. Appl. No. 62/079,916, filed Nov. 14, 2014. |
| U.S. Appl. No. 62/079,931, filed Nov. 14, 2014. |
| U.S. Appl. No. 62/079,939, filed Nov. 14, 2014. |
| Ulmer et al., “Stem Cells—Prospects in Dentistry”, Schweiz Monatsschr Zahnmed, vol. 120, Oct. 2010, pp. 860-872. |
| Umlauf et al., “Cartilage biology, pathology, and repair”, Cell. Mol. Life Sci., vol. 67, (2010), pp. 4197-4211. |
| Uriel et al., “The role of adipose protein derived hydrogels in adipogenesis”, Biomaterials, vol. 29, (2008), pp. 3712-3719. |
| Van der Donk, “Rinsing Morselized Allografts Improves Bone and Tissue Ingrowth”, Clinical Orthopaedics and Related Research, 2003, 408:302-310. |
| Voskerician et al., “Human Peritoneal Membrane Reduces the Formation of Intra-Abdominal Adhesions in Ventral Hernia Repair: Experimental Study in a Chronic Hernia Rat Model”, J. Surg. Res., vol. 157, pp. 108-114, 2011. |
| Wilson et al., “Adipose-derived stem cells for clinical applications: a review”, Cell Proliferation, vol. 44, (2011}, pp. 6-98. |
| Wilson et al., “Proteomic analysis of cartilage proteins”, Methods, vol. 45, (2008), pp. 22-31. |
| Wu et al., “Muscle-derived stem cells: isolation, characterization, differentiation, and application in cell and gene therapy”, Cell Tissue Res., vol. 340, (2010), pp. 549-567. |
| Xiao et al., “Clonal Characterization of Bone Marrow Derived Stem Cells and Their Application for Bone Regeneration” Int. J. Oral Sci., vol. 2, No. 3, (2010), pp. 127-135. |
| Xu, et al., “Umbilical Cord-Derived Mesenchymal Stem Cells Isolated by a Novel Explantation Technique Can Differentiate into Functional Endothelial Cells and Promote Revascularization”, Stem Cells and Development, vol. 19, No. 10, Oct. 2010, pp. 1511-1523. |
| Yoder et al., “Redefining endothelial progenitor cells via clonal analysis and hematopoetic stem/progenitor cell principals”, Blood, vol. 109, No. 5, Mar. 1, 2007, pp. 1801-1809. |
| Young et al., “Bone matrix proteins: their function, regulation, and relationship to osteoporosis”, Osteoporos Int., vol. 14 (Suppl 3), (2003), pp. S35-S42. |
| Young et al., “Injectable hydrogel scaffold from decellularized human lipoaspirate”, Acta Biomaterialia, vol. 7, (2011}, pp. 1040-1049. |
| Yun et al.. “Transcriptional Regulatory Networks Associated with Self-Renewal and Differentiation of Neural Stem Cells”, Journal of Cellular Physiology, vol. 225, published on line in Wiley Online Library (wileyonlinelibrary.com) Jul. 2010, pp. 337-347. |
| Zengin et al., Vascular wall resident progenitor cells: a source for postnatal vasculogenesis, Development, vol. 133, No. 8, (2006), pp. 1543-1551. |
| Zhang et al., “A nerve graft constructed with xenogeneic acellular nerve matrix and autologous adipose-derived mesenchymal stem cells”, Biomaterials, vol. 31, (2010), pp. 5312-5324. |
| Zouboulis et al., “Human skin stem cells and the ageing process”, Experimental Gerontology, vol. 43, (2008), pp. 986-997. |
| Communication Pursuant to Article 94(3) dated Sep. 4, 2020, for corresponding European Patent Application No. 16728155.9. |
| Mariman et al., “Adipocyte extracellular matrix composition, dynamics and role in obesity”, Cell. Mol. Life Sci., vol. 67, 2010), pp. 1277-1292. |
| Massirer et al., “Maintenance and differentiation of neural stem cells”, WIREs Systems Biology and Medicine, vol. 3, Jan./Feb. 2011, pp. 107-114. |
| Masuda, “Biological repair of the degenerated intervertabral disc by the injection of growth factors”, Eur. Spine J., vol. 7 (Suppl. 4), (2008), pp. S441-S451. |
| Mauney et al., “In vitro and in vivo evaluation of differentially demineralized cancellous bone scaffolds combined with human bone marrow stromal cells for tissue engineering”, Biomaterials, 26, 2005, pp. 3173-3185., 13 pages. |
| McNally et al., “Plantar Fascia: Imaging Diagnosis and Guided Treatment”, Seminars in Musculoskeletal Radiology, vol. 14, No. 3, {2010), pp. 334-343. |
| Meinel et al., “Bone Tissue Engineering Using Human Mesenchymal Stem Cells: Effects of Scaffold Material and Medium Flow,” Annals of Biomedical Engineering, vol. 32, No. 1, {Jan. 2004) pp. 112-122. |
| Meinel et al., “Engineering bone-like tissue in vitro using human bone marrow stem cells and silk scaffolds,” Journal of Biomedical Materials Research; 71A, pp. 25-34, {2004). |
| Meisel et al.; “Clinical experience in cell-based therapeutics: Disc chondrocyte transplantation A treatment for degenerated or damaged intervertebral disc”, Biomolecular Engineering, vol. 24, {2007), pp. 5-21. |
| Melero-Martin et al., “Concise Review: Vascular Stem Cells and Tumor Angiogeneses”, Stem Cells, vol. 29, {2011) pp. 163-168. |
| Mercuri, et al., “Novel tissue-derived biomimetic scaffold for regenerating the human nucleus pulposus”, J. Biomed. Mater. Res. A, vol. 96, No. 2, Feb. 2011, p. 35. |
| Metcalf, “Stem Cells, Pre-Progenitor Cells and Lineage-Committed Cells: Are Our Dogmas Correct?”, Annals New York Academy of Sciences, Feb. 6, 2006, pp. 289. |
| Miki et al., “Stem Cell Characteristics of Amniotic Epithelial Cells”, Stem Cells, vol. 23, {2005), pp. 1549-1559. |
| Minguell et al., “Mesenchymal Stem Cells”, Exp. Bioi. Med., vol. 226, No. 6, {2001), pp. 507-520. |
| Miyamoto et al., “Intradiscal transplantation of synovial mesenchymal stem cells prevents intervertebral disc degeneration through suppression of matrix metalloproteinase-related genes in nucleus pulposus cells in rabbits”, Arthritis Research & Therapy, vol. 12, {2010), pp. 1-13. |
| Mizuno, “Adipose-derived Stem Cells for Tissue Repair and Regeneration: Ten Years of Research and a Literature Review”, Journal of Nippon Medical School, vol. 76, No. 2, {2009), pp. 56-66. |
| Mulliken et al., “Use of Demineralized Allogeneic Bone Implants for the Correction of Maxillocraniofacial Deformities”, Annual Meeting of the American Surgical Association, 194 {3), 1981, pp. 366-372. 7 pages. |
| Murakami et al., “Quantitative differences in intervertebral disc-matrix composition with age-related degeneration”, Med. Bioi. Eng. Comput., vol. 48, {2010), pp. 469-474. |
| Murtuza et al., “Micro- and Nanoscale Control of the Cardiac Stem Cell Niche for Tissue Fabrication”, Tissue Engineering: Part B; vol. 15, No. 4, {2009), pp. 443-454. |
| Nilsen et al., “Cytokine profiles of cultured microvascular endothelial cells from the human intestine”, downloaded from gut.bmj.com on Dec. 18, 2012, pp. 635-642. |
| Rabie et al., The Effect of Demineralized Bone Matrix on the Healing of Intramembranous Bone Grafts in Rabbit Skull Defects, J. Dent. Res, vol. 75, No. 4, {Apr. 1996), pp. 1045-1051. |
| Non-Final Office Action for U.S. Appl. No. 13/108,856, dated Dec. 31, 2012. |
| Non-final Office Action for U.S. Appl. No. 13/108,856, dated Feb. 27, 2014. |
| Non-Final Office Action for U.S. Appl. No. 13/690,542, dated Nov. 24, 2014. |
| Non-Final Office Action for U.S. Appl. No. 13/828,525, dated Dec. 19, 2014. |
| Non-final Office Action for U.S. Appl. No. 13/828,525, dated Jan. 7, 2016. |
| Non-Final Office Action for U.S. Appl. No. 13/828,525, dated Oct. 7, 2016. |
| Non-Final Office Action for U.S. Appl. No. 13/948,798, dated Nov. 27, 2013. |
| Non-Final Office Action for U.S. Appl. No. 14/537,253, dated Nov. 25, 2015. |
| Non-Final Office Action for U.S. Appl. No. 14/933,176, dated Jul. 12, 2016. |
| Non-Final Office Action for U.S. Appl. No. 14/942,292, dated Nov. 2, 2016. |
| Office Action for European Patent Application No. 16 728 155, dated Jul. 11, 2019. |
| Office Action for U.S. Appl. No. 15/159,406, dated Aug. 7, 2017. |
| Oh et al., a new bone banking technique to maintain osteoblast viability in frozen human iliac cancellous bone; Cryobiology, vol. 44, {2002), pp. 279-287. |
| OPTP,The Anatomy of Fascia-Revealed! a discovery of 3-D continuity for MFR therapists, Feb. 2006, 2 pages. |
| Osathanon et al., “Basic fibroblast growth inhibits mineralization but induces neuronal differentiation by human dental pulp stem cells through a FGFR and PLCy signaling pathway”, Journal of Cellular Biochemistry, Mar. 4, 2011, pp. 807-1816. |
| Osteotech, Inc.: Xpanse® R Bone Insert—Introduction, web page printed Jun. 23, 2011, from http://osteotech.com/prodxpanseR.shtm, 1 page. |
| Pacifici et al., Mechanisms of Synovial Joint and Articular Cartilage Formation: Recent Advances, but Many Lingering Mysteries, Birth Defects Research {Part C), vol. 75, {2005), pp. 237-248 D. |
| Pacilli,“Vascular wall resident progenitor cells, A review”, Experimental Cell Research, vol. 315, {2009) pp. 901-914. |
| Pantou et al., “The effect of platelet-rich plasma {PRP) combined with a bone allograft on human periodontal ligament POL) cells,” Cell Tissue Bank, vol. 13, {2012), pp. 81-88. |
| Paterson et al.. “Dental tissue engineering products in the U.S. market to double by 2015”, Dental Tribune, Dec. 2009,p. 5A. |
| PCT Patent Application No. PCT/US2016/033246, Modified Demineralized Cortal Bone Fibers, filed May 19, 2016. |
| Peng et al., “Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Cartilage,and Adipose Tissue”, StemCells and Development, vol. 17, {2008), pp. 761-774. |
| Peng et al., “Mesenchymal Stem Cells and Tooth Engineering”, Int J Oral Sci, vol. 1, No. 1, {2009), pp. 6-12. |
| Peroni et al., “Stem molecular signature of adipose-derived stromal cells”, Experimental Cell Research, vol. 314, 2008), pp. 603-615. |
| Piekarz et al., “Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin as Monotherapy for Patients with Cutaneous T-Cell Tymphoma”, American Society of Clinical Oncology, vol. 27, No. 32, Nov. 10, 2009, pp. 5410-5412. |
| Pollen et al., “Stem Cells: attributes, cycles, spirals, pitfalls and uncertainties—Lessons for and from the Crypt”, Development, vol. 110, {1990), pp. 1001-1020. |
| Pretzel et al., “Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoarthritic and normal cartilage”, Arthritis Research & Therapy, vol. 13, R64, {2011 ), 37 pages, http://arthritis-research.com/content/13/2/R65. |
| Puetzer et al., “Comparative Review of Growth Factors for Induction of Three-Dimensional In Vitro Chondrogenesis in Human Mesenchymal Stem Cells Isolated from Bone Marrow and Adipose Tissue”, Tissue Engineering: Part B, vol. , No. 4, {2010), pp. 435-444. |
| Finnin et al., “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors”, Nature, vol. 401, Sep. 9, 1999, pp. 188-190. |
| Flynn et al., “Adipose tissue engineering with cells in engineered matrices”, Organogenesis, vol. 4, No. 4, {2008), pp. 228-235. |
| Flynn, “The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells”, Biomaterials, vol. 31, {2010) pp. 4715-4724. |
| Fong et al., “The Crowning Achievement: Getting to the Root of the Problem”, Journal of Dental Education, vol. 69, No. 5, May 2005, pp. 555-570. |
| Fraser et al., “Fat tissue: an underappreciated source of stem cells for biotechnology”, Trends in Biotechnology, vol. 24,No. 4,Apr. 2006,pp. 150-154. |
| Fuchs et al., “Building Epithelial Tissues from Skin Stem Cells”, Cold Spring Harb Symp Quant Bioi., vol. 73, {2008), pp. 333-350. |
| Gaissmaier et al., “Growth and differentiation factors for cartilage healing and repair”, Injury, Int. J. Care Injured, vol. 3951, {2008), pp. 588-596. |
| Gopinath et al., “Stem Cell Review Series: Aging of the skeletal muscle stem cell niche”, Aging Cell, vol. 7, {2008), pp. 590-598. |
| Gray's Anatomy of the Human Body, “Tendons, Aponeuroses, and Fasciae”, http://education.yahoo.com/reference/gray/subjects/subject/104, printed May 16, 2011, 2 pages. |
| Gregoire et al., “Understanding Adipocyte Ditferentiation”, Physiological Reviews, vol. 78, No. 3, Jul. 1998, pp. 783-809. |
| Grogan et al., “Mesenchymal progenitor cell markers in human articular cartilage: normal distribution and changes in osteoarthrtis”, Arthritis Research & Therapy, vol. 11, No. 3, Jun. 5, 2009, pp. 1-13. |
| Gronthos et al., “Surface Protein Characterization of Human Adiopose Tissue-Derived Stromal Cells”, Journal of Cellular Physiology, vol. 189, {2001 }, pp. 54-63. |
| Guilak et al., “The Pericellular Matrix as a Transducer of Biomechanical and Biochemical Signals in Articular Cartilage”, Ann. N.Y. Acad. Sci., vol. 1068, {2006), pp. 498-512. |
| Guimberteau, et al., “The Microvacuolar System: How Connective Tissue Sliding Works”, The Journal of Hand Surgery European Volume), vol. 35E, No. 8, {2010), pp. 614-622. |
| Halberg et al., “The Adipocyte as an Endocrine Cell”, Endocrinol Metab. Clin. North Amer., vol. 37, No. 3, Sep. 2008, pp. 753-767. |
| Han et al., “The Effect of Thrombin Activation of Platelet-Rich Plasma on Demineralized bone Matrix Osteoinductivity,” The Jounral of Bone and Joint Surgery, vol. 91, {2009), pp. 1459-1470. |
| Hardingham, “Extracellular Matrix and Pathogenic Mechanisms in Osteoarthritis”, Current Rheumatology Reports, vol. 10, {2008), pp. 30-36. |
| Heinegard et al., “The role of the cartilage matrix in osteoarthritis”, www.nature.com/nrrheum, Nat. Rev. Rheumatol., vol. 7, Jan. 2011, pp. 50-56. |
| Heller, “Soft Tissue, Fascia and the Adjustment”, http://chiroweb.com/mpacms/dc/article.php?=39&id=18250&no_paginate=true&p_friendly=true&no_b=true, printed Jun. 28, 2011. |
| Henriksson et al.. “Identification of Cell Proliferation Zones, Progenitor Cells and a Potential Stem Cell Niche in the intervertebral Disc Region”, Spine, vol. 34, No. 21, {2009), pp. 2278-2287. |
| Hidaka et al., “Regulatory Mechanisms of Chondrogenesis and Implications for Understanding Articular Cartilage Homeostasis”, Current Rheumatology Reviews, vol. 4, No. 3, {2008), pp. 1-12. |
| Hiraoka et al., “Mesenchymal progenitor cells in adult human articular cartilage”, Biorheology, vol. 43, {2006), pp. 147-454. |
| Hirschi et al., “Smooth Muscle Stem Cells”, The Anatomical Record Part A, vol. 276A, {2004), pp. 22-33. |
| Hodde et al. “Extracellular Matrix as a Strategy for Treating Chronic Wounds” Am J. Clin Dermatol, vol. 8, No. 2, 2007), pp. 61-66. |
| Hoell, et al.; “Auto ftuorescence of intervertebral disc tissue: a new diagnostic tool”, Eur Spine J, vol. 15 {Suppl. 3), 2006), pp. S345-S353. |
| Hollander et al., “Stem Cells and Cartilage Development: Complexities of a Simple Tissue”, Stem Cells, vol. 28, 2010), pp. 1992-1996. |
| Honda et al., “Dental follicle stem cells and tissue engineering”, Journal of Oral Science, vol. 52, No. 4, {2010), pp. 541-552. |
| Hsieh et al., “Cellular Mechanobiology of the Intervertebral Disc: New Directions and Approaches”, J. Biomech., vol. 43, No. 1, Jan. 5, 2010, 20 pages. |
| Huang et al., “Mesenchymal Stem Cells Derived from Dental Tissues vs. Those from other Sources: Their Biology and Role in Regenerative Medicine”, J. Dent. Res., vol. 88, No. 9, Sep. 2009, pp. 792-806. |
| Huntsman et al., “Lumbar Interbody Fusion With Osteosponge® Demineralized Allograft in a PEEK Cage as Compared to Fusion with rhBMP-2: 1 Year Post Operative Assessment,” dated Feb. 2009, from Bacterin International, Inc. website: www.bacterin.com, 4 pages. |
| Ingram et al., “Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells”, Blood, vol. 105, No. 7, Apr. 11, 2005, pp. 2783-2786. |
| International Search Report and Written Opinion for PCT/US2016/033246, dated Sep. 5, 2016. |
| Isolation of Stromal Stem Cells from Human Adipose Tissue, http://www.collaslab.com/UserFiles/File/Adipose%20stem%20cell%20isolation.pdf; article not dated, printed Jul. 20, 2011. |
| Jin et al., Human Amniotic Membrane as a Delivery Matrix for Articular Cartilage Repair, Tissue Engineering, vol. 13, No. 4,2007, pp. 693-702. |
| Jones et al.. “No place like home: anatomy and function of the stem cell niche”, Nature Reviews/Molecular Cell Biology, vol. 9, Jan. 2008, pp. 11-13. |
| Kajstura et al., “Evidence for Human Lung Stem Cells”, The New England Journal of Medicine, vol. 364, No. 19, May 12, 2011,pp. 1795-1806. |
| Karlsson et al., “Articular cartilage stem cell signalling”, Arthritis Research & Therapy, vol. 11, No. 4, Jul. 24, 2009, pp. 1-2. |
| Kilroy et al., “Cytokine Profile of Human Adiopose-Derived Stem Cells: Expression of Angiogenic, Hematopoietic, and Pro-Inflammatory Factors”, Journal of Cellular Physiology, vol. 212, {2007), pp. 702-709. |
| Koga et al., “Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions fo cell therapy of cartilage defects in rabbit”, Cell Tissue Res., vol. 333, {2008), pp. 207-215. |
| Kondo, et al. “Intervertebral Disc Development is Regulated by Wnt!JI-catenin Signaling”, Spine, vol. 36, No. 8, 2011 ), pp. E513-E518. |
| Kuhbier et al., “Stem cells from fatty tissue. A new resource for regenerative medicine?”, Chirug, vol. 81, {2010), pp. 826-832. |
| Kurth et al., “Functional Mesenchymal Stem Cell Niches in Adult Mouse Knee Joint Synovium In Vivo”, Arthritis & Rheumatism, vol. 63, No. 5, May 2011, pp. 1289-1300. |
| LaBarge et al., “Of Microenvironments and Mammary Stem Cells”, Stem Cell Reviews, vol. 3, No. 2, {2007) pp. 137-146. |
| Lahm et al., “Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases”, PNAS, vol. 104, No. 14, Oct. 30, 2007, pp. 17335-17340. |
| Lee, et al., “Mesenchymal Progenitor Cells Derived from Synovium and Infrapatellar Fat Pad as a Source for Superficial Zone Cartilage Tissue Engineering: Analysis of Superficial Zone Protein/Lubricin Expression”, Tissue Engineering: Part A, vol. 16, No. 1, {2010), pp. 317-325. |
| Li et al., “Human treated dentin matrix as a natural scaffold for complete human dentin tissue regeneration”, Biomaterials {2011), pp. 1-14. |
| Lin et al., “The Chondrocyte: Biology and Clinical Application”, Tissue Engineering, vol. 12, No. 7, {2006), pp. 1971-1984. |
| Lozito et al., “Mesenchymal Stem Cell Modification of Endothelial Matrix Regulates Their Vascular Differentiation”, Journal of Cellular Biochemistry, vol. 107, {2009), pp. 706-713. |
| Lyngstadaas et al., “Enamel matrix proteins; old molecules for new applications”, Orthod Craniofac Res., vol. 12, No. 3, Aug. 2009, pp. 243-253. |
| Lynn, et al., “Antigenicity and Immunogenicity of Collagen”, published online Jul. 16, 2004 in Wiley InterScience {www.Interscience.wiley.com), pp. 343-354. |
| Number | Date | Country | |
|---|---|---|---|
| 20200046501 A1 | Feb 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62331071 | May 2016 | US | |
| 62164827 | May 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15159406 | May 2016 | US |
| Child | 16598354 | US |
